

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁴ : A61K 49/00, C07D 219/04 C07D 263/62, C07C 87/14	A1	(11) International Publication Number: WO 89/10758 (43) International Publication Date: 16 November 1989 (16.11.89)	
(21) International Application Number: PCT/US89/00087 (22) International Filing Date: 10 January 1989 (10.01.89) (30) Priority data: 189,192 2 May 1988 (02.05.88) US (71) Applicant: ZYNAXIS TECHNOLOGIES, INC. [US/US]; 5 Great Valley Parkway, Malvern, PA 19355 (US). (72) Inventors: HORAN, Paul, Karl ; 30 Heron Hill Drive, Downingtown, PA 19355 (US). SLEZAK, Sue, Ellen ; 209 Valley View Lane, Downingtown, PA 19335 (US). GRAY, Brian, David ; 2307 Haverford Road, Apt. A, Ardmore, PA 19003 (US). DUNN, Georges, L. ; 690 Mallard Road, Wayne, PA 19087 (US).		(74) Agent: HAGAN, Patrick, J.; Dann, Dorfman, Herrell & Skillman, Three Mellon Bank Center, Suite 900, 15th Street and South Penn Square, Philadelphia, PA 19102-2440 (US). (81) Designated States: AT (European patent), AU, BE (Euro- pean patent), CH (European patent), DE (European pa- tent), DK, FI, FR (European patent), GB (European pa- tent), IT (European patent), JP, KR, LU (European pa- tent), NL (European patent), SE (European patent). Published <i>With international search report</i> <i>With amended claims</i>	
(54) Title: COMPOUNDS, COMPOSITIONS AND METHOD FOR BINDING BIO-AFFECTING SUBSTANCES TO SURFACE MEMBRANES OF BIO-PARTICLES (57) Abstract Compounds, compositions, their methods of preparation and use in binding bio-affecting substances to the surface mem- brane of bioparticles, such as eukaryotic cells, without producing appreciable detrimental effect on morphology or physiological function of cells.			

BEST AVAILABLE COPY

COMPOUNDS, COMPOSITIONS AND METHODS FOR BINDING
BIO-AFFECTING SUBSTANCES TO SURFACE MEMBRANES
OF BIO-PARTICLES

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates to compounds for binding bio-affecting substances, such as therapeutic and diagnostic agents, to the surface membrane of viable bio-particles, including eukaryotic prokaryotic cells and viruses, without producing appreciable detrimental effects on morphology or physiological function of the bio-particle to which the compounds are bound. The invention also relates to compositions and methods enabling binding of such compounds to bio-particles and to the use of the resultant particles for producing a site-specific predetermined effect, e.g., a diagnostic or therapeutic effect, in vivo.

Background Information

Numerous compounds and compositions are known which are capable of binding bio-affecting substances to carrier cells for various diagnostic applications. Fluorescent labeling techniques using a wide range of fluorochromes have been reported, such as cyanine derivatives, U.S. Patent No. 4,343,782, fluorescein isothiocyanate, Butcher et al., J. Immunol. Methods, 37, 109-21 (1980) and Butcher et al., J. Immunol. Methods, 37, 97-108 (1980) and fluorescein or rhodamine having a single, relatively long aliphatic hydrocarbon substituent, Wanda et al., J. Histochem. Cytochem., 30, 1297-1300 (1982). There has also been reported a

non-reproducible labeling technique using
3,3'-di-n-octodecyloxacarbocyanine for retrograde
labeling of neurons Honig et al., J. Cell Biology, 103,
171-87 (1986). These prior art cell labelling compounds
5 have been found to be: 1) unstable in the plasma
membrane for long periods of time, and/or 2) cytotoxic
or otherwise detrimental to cell function or morphology,
and/or 3) not capable of providing reproducible results.

Diagnostic techniques utilizing chelate-metal ion
10 complexes for radiographic and nuclear magnetic
resonance imaging are fairly well developed. The use of
complexes of Gallium-67, Indium-111, and Technetium-99m
in radio-imaging techniques have been widely reported.
See, for example, Holman, ed., Radionuclide Imaging of
15 the Brain (New York:Churchill Livingstone, 1985). The
use of paramagnetic complexes in NMR imaging has been
extensively investigated and compositions including such
complexes have been proposed for administration as image
enhancers. See, Australian Patent application 86 330/82
20 of Greis et al., filed July 22, 1982. Insofar as is
known, however, such imaging techniques do not result in
membrane binding but rather the imaging complex is taken
up into the cell and binds to the reticulum of the cell.
In these applications, the chelating agent, e.g., oxine,
25 tropolone or merc, have a toxic effect on many cells,
such as lymphocytes, and are not optimal for imaging.
Furthermore, since the detectable metal ion is taken
into the cell, isotopic decay can more easily result in
radiation damage to the cell's genetic material.

30 European Patent application Serial No. 86103694.5,
published October 22, 1986, describes a method for the
selective irradiation of biological materials,

particularly tissues, cells or cell components, in which the Mossbauer absorption frequency of a component of the material to be irradiated is determined and the material is then irradiated with gamma radiation of the
5 corresponding Mossbauer absorption frequency with internal conversion and emission of gamma radiation and/or Auger electrons. The method is disclosed as being useful for selective radiation therapy providing selective tissue damage or necrosis, e.g., in cancer
10 therapy, and for differentiating between diseased and healthy tissues. In practicing this method, Mossbauer isotopes are administered parenterally but are not selectively delivered to the tumor cells. It is believed that the selectivity in tumor cell kill will be
15 achieved either through differences in absorption wavelengths of Mossbauer atoms within tumor cells and normal cells or by specifically focusing the absorbed radiation at the tumor itself.

One of the major goals of any pharmaceutical
20 development is to provide drug therapy which is totally specific for a target cell type or disease site. In some cases, the compounds used are antagonists or agonists where specific receptors are found on cells to which therapy is directed and lower levels or affinities
25 on other cell types. In other cases, the drug is specifically taken up by cells at the disease site or metabolized at the disease site in a way which is different from the metabolism at non-disease sites.

In treating cancer, many drug therapies proceed on
30 the assumption that cancer cells are growing and metabolizing at a rate which is greater than most non-tumor cells. This assumption generally is flawed by

the fact that hair follicles, bone marrow cells and gastro-intestinal cells grow at even faster rates and are often quite affected by these therapies. But even in cancer therapies, the goal is to try to deliver the
5 therapy only to the tumor cells.

One recent attempt at this goal is to use monoclonal antibodies, as described in European Patent No. 83400461.6. With this therapy, the monoclonal antibody has "specific" binding affinity for the tumor
10 cells. Radio-therapy or chemotherapeutic molecules are bound (covalent or ionic) to the monoclonal and injected intravenously into the patient. The monoclonal then migrates to the tumor site where it binds to the tumor cells with sufficiently high affinity to allow for the
15 accumulation of radiation or chemical damage to be accrued by the tumor cells. This "therapy" is fraught with a number of problems, not the least of which is the large amount of protein which must be injected for each treatment, making this therapy quite expensive.
20 Additionally, the monoclonals injected are foreign protein and often results in the generation of antibodies by the patient against the therapeutic molecule. Furthermore, specificity of binding is often a problem and non-specific toxicity is the result.
25 Antigen shedding or modulation is equally problematic for this methodology, as well as limited capability to enter poorly vascularized tumors. In general, a methodology which could deliver a desired therapeutic effect specifically to tumor sites, is a desirable
30 attribute for a pharmaceutical substance.

In copending U.S. Patent application Serial No. 925,192, filed October 31, 1986, methods are

disclosed for reproducibly labeling viable cells with symmetrical cyanine dyes that do not significantly affect cell viability. Applications for such labeled cells include using labeled red blood cells to

- 5 distinguish post-transfusional bleeding from immunologic reaction and using dilution to measure growth rate of cultured cells.

In copending U.S. Patent application Serial No. 925,445, filed October 31, 1986, methods are disclosed
10 for tracking cells in vivo and for determining in vivo cell lifetimes. In performing such methods, cells are labeled with cyanine dyes and detection is by measuring fluorescence, absorbance, or by detecting nuclear magnetic resonance probes included in the cyanine dyes.
15 The methods are useful, for example, to measure red blood cell and platelet lifetimes, to track cells to determine sites of primary or metastatic tumors, or sites of occult infection, and to determine rates at which cells pass through vessels for assessing blood
20 vessel patency and platelet aggregation.

In copending U.S. Patent application Serial No. 925,429, filed October 31, 1986, methods are disclosed for determining growth rate of cells growing in vivo and in vitro. In carrying out such methods, cells are
25 labeled with cyanine dyes and changes in plasma membrane cyanine dye levels are used to determine growth rate. The resulting cell growth rate determinations are utilized to monitor transplanted bone marrow cell engraftment and post-surgical corneal epithelial cell
30 growth. Such methods also are useful for determining tumor cell sensitivity to cancer therapeutic

agents, yeast sensitivity to antifungal agents, bacteria sensitivity to antifungal agents, and bacteria sensitivity to antibacterial agents.

SUMMARY OF INVENTION

5 It has now been discovered that bio-affecting compounds may be reproducibly bound to the surface membrane of cells, both eukaryotic and prokaryotic, and to viruses with sufficient affinity to prevent dissociation of the compound from the membrane and
10 without adversely affecting the normal functioning of the cell or virus.

 According to one aspect of the invention, compounds are provided having the capability of binding in the lipid phase of the surface membrane of cells or viruses.
15 These compounds comprise a bio-affecting moiety, preferably a diagnostic or therapeutic agent, and at least one hydrocarbon substituent selected so that the compound is sufficiently non-polar as to have a surface membrane retention coefficient of at least 90 over 24
20 hours in saline containing 10 percent serum and further selected so that the compound solubility determination factor of the compound has no more than a 20% change over a two hour time period in the binding medium of choice. Suitable compounds are those of the formula R -
25 B - R₁, wherein B represents the bio-affecting moiety and R and/or R₁ represent relatively long chain hydrocarbon substituents or "tails" that impart the requisite lipophilicity to the compounds. Once embedded in the membrane of a cell or virus the compounds do not
30 appreciably adversely influence the normal function thereof, or have detrimental effect on viability of cells or viruses to which they are bound, which cells are sometimes referred to herein as carrier cells or

viruses.

The number of linear carbons in the hydrocarbon tail(s) of the compounds of the invention is an important factor in achieving binding of the compounds of the invention to surface membranes of prokaryotic or eukaryotic cells or viruses. Experience with use of cyanine derivatives as diagnostic agents indicates that hydrocarbon tails of less than 3 carbons causes the cyanine to penetrate the plasma membrane and the nuclear membrane of cells resulting in staining of RNA and DNA. If carbon tails have a length greater than 3 carbons and less than 12 carbons, the compound no longer binds RNA and DNA but responds to membrane potential and enters the mitochondria (U.S. Patent No. 4,343,782 to Shapiro and U.S. Patent No. 4,424,201 to Valinsky, T. J. Lampidis et al., Agents and Actions, 14, 751-757, 1984). When the sum of the linear carbons in the hydrocarbon tail(s) is 23 or greater the lipophilicity of the molecule is increased such that it is retained in the plasma membrane and will not leak or transfer to other cells. In general, the longer the hydrocarbon tail, the higher the lipophilicity. Hydrocarbon tails having more than 30 linear carbon atoms, however, may pose a problem because the bio-affecting moiety and the reactant used to provide the hydrocarbon tail may not be soluble in the same solvent, making the chemistry of joining the hydrocarbon tail to the bio-affecting moiety quite difficult. Thus, there may be a practical limitation on the length of the hydrocarbon tail(s) depending on the chemical nature of the bio-affecting moiety to which it is to be bound.

According to another aspect of the invention, there is provided a composition for binding a bio-affecting moiety to a carrier cell or virus, which comprises a

compound of the invention dissolved in a medium which is iso-osmotic for the cell or virus to which the compound is bound and which allows for consistent solubility of the compounds, with the dissolved compound being in a form that reproducibly binds to plasma membranes. The cell binding media which may be used in the practice of this invention include sugars, sugar-alcohols, amino acids, a Good's buffer, or a combination thereof, in which the compounds of the invention are stably soluble.

According to a further aspect of the invention, there is provided a method for preparing a carrier cell bearing a bio-affecting moiety capable of reproducibly exerting a site-specific predetermined effect, e.g., a diagnostic or therapeutic effect, in vivo. The desired effect may be exerted, for example, directly on a carrier cell, or on a cell group comprising such carrier cell. The preparative method essentially involves contacting a compound of the invention with the carrier cell or virus in the presence of a medium of the type described above, under conditions causing binding of the compound to the carrier cell or virus. The preparative method of the invention occurs without appreciably diminishing viability of the carrier cell or virus, or otherwise adversely affecting the desired physiological function thereof.

According to yet another aspect of the invention, there is provided a method for exerting a site-specific predetermined effect in vivo by exposure of the target site to a bio-affecting moiety capable of producing the desired effect. The method involves providing a carrier cell or virus to which is bound a compound of the invention, and delivering the bound carrier cell or

virus to the site where the bio-affecting moiety is to produce its intended effect.

The present invention possesses a number of advantages as compared with the above-discussed prior art particularly with respect to applications involving cell binding. First, the compounds of the invention are bound to carrier cells in such a way as to place the bio-affecting substituent on the exterior of the cell. In many applications this provides a distinct advantage versus prior art techniques for binding bio-affecting substances to cells, in which the bio-affecting substance is caused to penetrate beyond the plasma membrane and into the cytoplasm or mitochondria. In radio-isotope labeling, for example, placement of Indium or Technetium on the outside of the plasma membrane lowers the probability that emitted gamma radiation will pass through the nucleus of the cell, thus reducing the risk of undesired mutation or cell death. Such disruption of normal cell function is a serious problem with radiopharmaceuticals, such as the Indium-oxine or Indium-tropolone which are currently used. As a result of carrier toxicity and Indium toxicity upon the host cell such methods are considered sub-optimal for labeling of lymphocytes.

Furthermore, where toxic, chemotherapeutic, or radiotherapeutic agents are bound to the plasma membrane of a cell as the bio-affecting moiety in accordance with the invention, the carrier cell avoids the toxic or chemotherapeutic effects but travels to the target site where the intended toxic or chemotherapeutic effect of the bio-affecting moiety is exerted on surrounding cells.

In other applications, monoclonal antibodies,

lectins, agonists or antagonists to tissue receptors, glycosaminoglycans, sialic acids or other such molecules may be placed on the exterior surface of the cell to alter the migration patterns of the cell. While some
5 biomolecules such as glycosaminoglycans and sialic acids may affect specific migration routes, others like monoclonal antibodies, agonists or antagonists to tissue receptors, or lectins may effect the retention time of a cell at a specific site.

10 A further notable advantage is that binding of the compounds of the invention to carrier cells occurs in the lipids. This is significant because binding in lipids reduces the chance of interfering with the important functional domains of a cell membrane which
15 lie in the discrete protein portions and not in the more extensive lipid regions. Those prior art procedures for delivering bio-affecting substances to cells which involve binding to proteins and cell receptors often result in diminished functional
20 capacity, as noted above.

There are certain concomitant benefits realized from binding in the lipid regions of cells. Since the lipid regions comprise the vast majority of the surface area of the cell, it is possible to place larger numbers
25 of lipid binding compounds into the plasma membrane. Moreover, because the compounds of the invention are incorporated into membrane lipids, they are generally insoluble in normal physiological salts. Accordingly, once the compounds are bound to the membrane, they are
30 effectively trapped there and cannot dissociate easily. Consequently, the compounds do not leak from the cells, and when a labeled cell encounters another cell or membrane, the compound is not transferred from cell to

cell.

Binding in the membrane lipids is also advantageous in that the bound compounds are generally non-immunogenic. The immune system does not respond as readily to changes in the lipid regions of the cell membrane as to changes in the protein portion. Thus, with a sufficiently small bio-affecting moiety, the compounds of the invention would not be expected to generate a humoral or cellular immune response against them. If, on the other hand, a cellular or humoral response is desired, it is possible to use bio-affecting moieties of sufficient size and immunogenicity to elicit the desired response, which might be beneficial, for example, in vaccine production.

Knowledge of the migration patterns of immune and hematopoietic cells to specific disease sites is also used to advantage in the practice of this invention. With such information, compounds of this invention may be administered to target therapeutic molecules to the site of disease and only minimally affect non-disease sites.

Using cell targeting therapies, the therapeutic-agent will not enter the liver cells, unless the cell to which it is bound is dead. In this way, the optimal therapeutic effect will be exerted on the specific site to which the bound cell migrates, as metabolism of the therapeutic agent in the liver will be avoided.

Brief Description of the Drawings

Referring to the drawings herein,

Fig. 1 graphically represents fluorescence intensity distribution measurements for Yac-1 cells labeled with DiO-Cl4-(3), with Fig. 1A showing the intensity difference of stained versus non-stained cells; and Fig. 1B showing a decrease in fluorescence intensity as a function of time.

Fig. 2 graphically represents cell number and inverse fluorescence intensity measurements as a function of time using DiO-Cl4-(3)-labeled and unlabeled Yac-1 cells.

Fig. 3 is a graphical representation showing the correlation with respect to cytotoxicity of DiO-Cl4-(3) stained and non-stained Yac-1 targets.

Fig. 4 is a graphical representation showing the correlation with respect to cytotoxicity of effector/target staining using DiO-Cl4-(3) stained Yac-1 targets and unstained Poly I:C treated NK-preps, versus unstained Yac-1 targets and stained Poly I:C treated NK-preps.

Fig. 5 illustrates the cell binding stability of a compound of the invention as compared with two different fluorescent compounds with unacceptable levels of release from the plasma membrane of labeled cells.

DETAILED DESCRIPTION OF INVENTION

The expression "viable bioparticle capable of physiological function" is used herein to refer to any viable cell or membrane-containing virus. Moreover, as
5 used herein, the term "cell" includes prokaryotic cells, such as bacteria, as well as nucleated eukaryotic cells, such as white blood cells, various tumor cells, and mammalian cells in culture, e.g., chinese hamster ovary cells, yeast, and non-nucleated cells, such as red blood
10 cells, red blood cell ghosts and platelets. The detailed description of the invention hereinbelow is set forth with particular reference to cells. It should be understood, however, that what is stated with respect to cells is generally applicable to membrane-containing
15 viruses, as well.

The terms bio-affecting substance and bio-affecting moiety are used interchangeably herein to refer to a wide variety of different substances useful in the therapeutic, diagnostic, prophylactic or other treatment
20 of humans or animals. The substances useful in therapeutic applications of the invention include those capable of preventing, alleviating, treating or curing abnormal or pathological conditions of the living body. The diagnostic applications of the compounds include,
25 for example, determination or detection of a physiological condition or state by an in vivo or in vitro test. The bio-affecting substances useful in the practice of this invention further include those capable of maintaining, increasing, decreasing, limiting or
30 destroying a physiologic body function, as well as substances for protecting a living body by inhibiting, killing, modifying or retaining a microorganism or antigen thereof. Derivatives of such substances having

long hydrocarbon tails, as described in further detail below, may be beneficially used in any of these general categories of application. Particularly preferred are bio-affecting moieties which function as diagnostic or
5 therapeutic agents.

In the case of diagnostic applications, the compounds of the invention effectively serve as reporter molecules which may be detectable from outside the body, or may require removal of a body fluid or biopsy for
10 analysis in vitro, the former procedure, allowing for non-surgical assessment of a physiological condition, may be preferred.

When used in therapeutic applications, a compound of the invention is bound to a selected cell type and
15 introduced into the body with the result that the desired therapy is directed against the abnormal or pathological condition, or the normal migration or circulation pattern of the carrier cell is altered, so that the therapeutic agent is delivered, as desired. In
20 any case, the compounds of the invention exhibit no appreciable cytotoxic effect on the carrier cell, nor otherwise produce any appreciable detrimental effect on desired cell function.

The diagnostic agents comprising the compounds of
25 the invention may be selected from diverse classes of substances that are detectable by various analytical procedures known to those skilled in the art. One such class of substances suitable for diagnostic application includes those in which the bio-affecting moiety is a
30 fluorescent compound. A composition comprising such a compound in a solvent of the type described herein may be readily applied to carrier cells so that the compound is bound to the plasma membrane of the cells. The cells

are then rendered fluorescent, and are thus detectable ex vivo, thereby providing some indication about in vivo activity of the cell. Such fluorescent compounds are preferably cyanine dyes and their derivatives, including, e.g., oxacarbocyanine, indocarbocyanine, thiocarbocyanine, or acridine dyes and derivatives thereof. Other useful fluorescent compounds include, for example, styrylpyridine, anthraquinone, coumarin, xanthene, phenoxazine, phenothiazine, or diphenylhexatriene dyes and derivatives thereof. The fluorescent moieties preferably have a positive charge which helps in incorporation and retention in the plasma membrane.

Other useful diagnostic agents are chelating substances complexed with metals, which may be directly or indirectly detectable. Thus, the chelate-metal complex may comprise an isotope selected from the transition metal series whose atomic number is from 21-49, such as Indium-111 or Technetium-99m. Such complexes may be bound to the cell plasma membrane rendering it radioactive, so as to permit imaging using a gamma camera after injection of the labeled cells into the body. Chelating substances may also be complexed with an ionic species of metal which is indirectly detectable, e.g., by reason of certain effects produced thereby at the site of interest. Complexes of paramagnetic elements, for example, are capable of influencing the relaxation times of nearby nuclei, which is detectable by magnetic resonance imaging (MRI).

Chelate-metal complexes comprising a metal ion selected from the transition metal series whose atomic number is from 21-29, the lanthanide series whose atomic number is 59-66 and the actinide series whose atomic number is 91,

may be suitable for such purpose.

Compounds comprising radioisotopic atoms may also be used, if desired, in diagnostic applications of this invention. A radioisotope such as ^{125}I ,
5 ^{131}I , ^{14}C , ^3H , ^{32}P , ^{35}S , ^{75}Se
may be substituted for the more abundant but non-radioactive form of the naturally occurring atom present in the bio-affecting moiety or the hydrocarbon tail portion of the compound. A suitable formulation of
10 such compound applied to carrier cells (or viruses), so that the compound is bound to the plasma membrane of the cells (or membrane of the virus), renders the cells (or viruses) radioactive and permits imaging using conventional radiographic detection equipment, such as a
15 gamma camera or standard beta counting procedures. Isotopes having non-zero spin states may also be introduced into the compounds of the invention, so as to make their presence detectable using MRI techniques.

For therapeutic applications, the bio-affecting
20 moiety may be a chelating agent of the type described above, complexed with an alpha-emitting radionuclide, or a moderate energy beta emitting isotope, such as ^{67}Cu . A composition of such a complex in an appropriate solvent is bound to carrier cells and washed
25 carrier cells are injected into the patient for delivery to the disease site to provide local radiation sufficient to interrupt the disease process.

As another form of the therapeutic bio-affecting moiety, a chelating agent may be complexed with a
30 Mossbauer isotope. A formulation of said complex could be applied to cells for injection into the patient, where they would track to the disease site. Thereafter, a low level of whole or partial body radiation of

appropriate wave length would be applied so that the Mossbauer atom could absorb the applied radiation, emitting Auger electrons in a manner analogous to the procedure described in European Patent Application
5 Number 86103694.5, supra, which provides numerous examples of Mossbauer isotopes useful for this purpose. In this particular application, however, since the carrier cells would deliver the Mossbauer isotope to the disease site, the radiation could be administered
10 without having to determine the location of the disease site in advance.

Proteinaceous substances, including proteins, glycoproteins, lipo-proteins or peptides may also be coupled to hydrocarbon tails of appropriate length for
15 the therapeutic applications in accordance with the present invention. Representative bio-affecting proteinaceous substances are toxins, hormones, enzymes, antigens, antibodies and antibody fragments. An appropriate formulation of such compound would be
20 applied to cells for injection into a patient. For example, tPA may be bound to the surface of a red cell, which, when delivered to a fibrin clot, dissolves the fibrin to permit reperfusion. The tPA would be expected to have no appreciable effect on the carrier
25 cell to which it is bound. Similarly, antibody molecules may be bound to the surface of a monocyte and, while having no effect on the monocyte, may bind to a tumor cell and direct the monocyte to kill the tumor cell.

30 In another therapeutic application of the compounds of the invention, the bio-affecting moiety is a carbohydrate capable of altering the migration and circulation patterns within the body of cells to which


it is bound. One class of carbohydrates applicable in this way includes sialic acids; another includes the glycosaminoglycans. For example, a formulation comprising a sialic acid could be applied to the plasma
5 membrane of red cells to increase the number of sialic acids on the membrane. The increase in the number of charge groups should increase the lifetime of the red cells in circulation before removal in the liver.

The bio-affecting moiety may also be in the form of
10 a ligand capable of binding to receptors on cells within target organs. Compounds containing such ligands, when bound to cells, would enable the migration of cells to be directed to specific organ sites.

The bio-affecting moieties are used in the form of
15 derivatives which enable binding to the plasma membrane of carrier cells. These derivatives are compounds of the formula $R-B-R_1$ wherein B represents a bio-affecting moiety and R and R_1 represent substituents independently selected from the group of
20 hydrogen, alkyl, alkenyl, alkynyl, alkaryl or aralkyl, the hydrocarbon chains of which are linear or branched, the substituents being unsubstituted or substituted with one or more non-polar functional groups, one of R or R_1 having at least 12 linear carbon atoms and the sum
25 of the linear carbon atoms in R and R_1 totalling at least 23, and provided that when B represents cyanine, R is different from R_1 . The R and/or R_1 groups are so selected that the plasma membrane retention coefficient of the compound (as described below) is at least 90 over
30 24 hours in saline containing 10% serum, and that the compound solubility determination factor of the compound has no more than a 20% change over a two hour time period in the binding medium of choice. As used

herein, the expression "non-polar functional group" refers to substituents such as O-alkyl, S-alkyl, halogen, N(alkyl)₂, Se-alkyl, NO, CN, CO-alkyl, C=N-alkyl, -SiMe₃, O-SiMe₃, and the like.

- 5 A preferred class of fluorescent compounds within the scope of the invention are cyanine derivatives of the formula



- wherein R and R₁ are different and represent substituents independently selected from the group of
 15 hydrogen, alkyl, alkenyl, alkynyl, alkaryl or aralkyl, the hydrocarbon chains of which having from 1 to 30 carbon atoms, and being linear or branched, said substituents being unsubstituted or substituted with one
 20 having at least 12 linear carbon atoms, and the sum of the linear carbon atoms in R and R₁ being at least 23;

X and X₁ may be the same or different and represent O, S, C(CH₃)₂ or Se;


- 25 Y represents a linking group selected from -CH=, -CH=CH-CH=, -CH=CH-CH=CH-CH=, or -CH=CH-CH=CH-CH=CH-CH=;

- Z represents a substituent selected from the group H, alkyl, OH, NH₂, COOH, CONH₂, SO₃H, SO₂NH₂,
 30 CONH-alkyl, CON-(alkyl)₂, NH-acyl, -O-alkyl, NH-alkyl, or N(alkyl)₂, SH, S-alkyl, NO₂ or halogen, the alkyl groups comprising said Z substituents having from 1 to 3 carbon atoms;

and A represents a biologically compatible anion.

Particularly good results in the practice of this invention are achievable using cyanine derivatives of

the formula




wherein R and R₁ are different and represent alkyl substituents, having from 1 to 30 carbon atoms, and being linear or branched, unsubstituted or substituted with halogen, one of R or R₁ having at least 12 linear carbon atoms and the sum of the linear atoms in R and R₁ being at least 23;

Z represents a substituent selected from the group II, or lower alkyl having from 1 to 3 carbon atoms; and

A represents a biologically compatible anion.

Another preferred class of fluorescent compounds within the scope of the invention are acridine derivatives of the formula



wherein R represents a substituent selected from the group of alkyl, alkenyl, alkynyl, alkaryl or aralkyl, the hydrocarbon chain of which is linear or branched, said substituent being unsubstituted or substituted with one or more non-polar functional groups, and having at least 23 linear carbon atoms;


Z represents a substituent selected from the group II, alkyl, OH, NH₂, COOH, CONH₂, SO₃H, SO₂NH₂, CONH-alkyl, CON(alkyl)₂, NH-acyl, -O-alkyl, NH-alkyl, or N(alkyl)₂, SH, S-alkyl, NO₂, halogen, the alkyl groups comprising said Z substituents having from 1 to 3 carbon atoms; and

A represents a biologically compatible anion.

A further preferred class of compounds within the

scope of the invention are chelating agents of the formula

A chelating agent having the formula:




, n being a number from 0 to 2; m being a number from 0 to 2; and p being either 0 or 1,

wherein R₁, R₂, R₃ and R₄ independently represent substituents selected from the group of:

H, CH₂COOH

15



C₁-C₃₀ alkyl, C₁-C₃₀ alkenyl, C₁-C₃₀ alkynyl, and unsubstituted or substituted aryl or aralkyl, said last-mentioned substituents being selected from hydroxyl, halogen, thiol, C₁-C₃₀ alkyl, C₁-C₃₀ alkenyl, C₁-C₃₀ alkynyl or aryl or aralkyl; O-(C₁-C₃₀ alkyl, alkenyl or alkynyl); S-(C₁-C₃₀ alkyl, alkenyl or alkynyl); NH(C₁-C₃₀ alkyl, alkenyl or alkynyl); N⁺R₁₁ (C₁-C₃₀ alkyl, alkenyl or alkynyl)₂; N(C₁-C₃₀ alkyl, alkenyl or alkynyl)₂

30

W represents CH_2 or $\text{C}=\text{O}$;

X represents CH or N ;


R_5 and R_5' independently represent H , $\text{CH}_2\text{CO}_2\text{H}$, or $\text{Y}-\text{R}_8$;

5 Y represents the linking group O , $\text{C}=\text{O}$, S , $(\text{CH}_2)_x$ or Se , x being a number from 0 to 5;

R_6 and R_7 independently represent H or C_1 to C_2 alkyl;

R_8 represents a substituent selected from the
 10 group of $-\text{NH}(\text{C}_1-\text{C}_{30}$ alkyl, alkenyl, or alkynyl),
 $\text{N}(\text{C}_1-\text{C}_{30}$ alkyl, alkenyl or alkynyl) $_2$,
 $\text{N}^+\text{R}_{11}(\text{C}_1-\text{C}_{30}$ alkyl, alkenyl or alkynyl) $_2$,
 C_1-C_{30} alkyl, C_1-C_{30} alkenyl, C_1-C_{30}
 alkynyl, unsubstituted or substituted aryl or aralkyl,
 15 said last-mentioned substituents being selected from the
 group of H , alkyl to C_{30} , alkenyl to C_{30} ,
 alkynyl to C_{30} , alkaryl, aralkyl, $-\text{O}$ -alkyl to
 C_{30} , $-\text{O}$ -alkenyl to C_{30} , O -alkynyl to C_{30} ,
 $-\text{O}$ -aralkyl, $-\text{NR}_9$ -alkyl to C_{30} , $-\text{NR}_9$ -alkynyl to
 20 C_{30} , $-\text{NR}_9$ -alkenyl to C_{30} , $-\text{NR}_9$ -aralkyl,
 S -alkyl to C_{30} , $-\text{S}$ -alkenyl to C_{30} , S -alkynyl to
 C_{30} , $-\text{S}$ -aralkyl, $\text{N}^+\text{R}_9\text{R}_{11}$ -alkyl to C_{30} ,
 $\text{N}^+\text{R}_9\text{R}_{11}$ -alkenyl to C_{30} ,
 $\text{N}^+\text{R}_9\text{R}_{11}$ -alkynyl to C_{30} , $-\text{NHCO}\text{R}_9$,

25



y being a number from 0 to 5;

R_9 represents a substituent selected from the
 30 group of

H , C_1-C_{30} alkyl, C_1-C_{30} alkenyl,
 C_1-C_{30} alkynyl or aralkyl;


R_{10} represents a substituent selected from the

group of C₁-C₃₀ alkyl, C₁-C₃₀ alkenyl,
C₁-C₃₀ alkynyl, alkaryl or aralkyl;

R₁₁ represents a substituent selected from the
group of H or C₁ to C₃ alkyl; and

5 wherein at least one of the substituents R₁,
R₂, R₃, R₄, R₈, R₉ or R₁₀ has a minimum of
23 carbon atoms, or the sum of the linear carbon atoms
in any two of said substituents totals at least 23
carbon atoms.

10 Particularly preferred are chelating agents of the
following formulae:



wherein R₁ represents COCH₂SH,
CH(CH₃)C(CH₃)=NOH or CH₂C(Me)₂SH;


20 X represents a carbonyl or methylene; and

R₂ represents a substituent selected from the
group of NHR₃, NR₃R₄ or ⁺NR₃R₄R₅;

R₃ and R₄ represent substituents independently
selected from the group of C₁-C₃₀ alkyl,
C₁-C₃₀ alkenyl, C₁-C₃₀ alkynyl, aralkyl or
25 alkaryl;

R₅ represents H or C₁ to C₂ alkyl; and at
least one of the substituents R₃ or R₄ has a minimum
of 23 linear carbons, or the sum of linear carbon atoms
in R₃ and R₄ totals at least 23 carbon atoms.

30 Also useful are chelating substance of the
formula:



wherein n is 0 or 2; m is 1 or 2; X represents CH or N; one of R₁ or R₂ is CH₂CO₂H and the other of R₁ or R₂ represents a substituent selected from the group of alkyl, alkenyl, alkynyl, aralkyl or alkaryl, or
5 CH₂-C₆H₄-NHCO-(alkyl, alkenyl, alkynyl, aralkyl, alkaryl), the hydrocarbon chain of which is linear or branched and contains at least 23 linear carbon atoms. Chelating agents of this formula are preferably
10 complexed with Indium. Of course, various other lipophilic chelating derivatives may be used in the practice of this invention, if desired.

A number of different synthetic routes may be used in preparing derivatives of bio-affecting substances having the formula R-B-R₁, as described above. These
15 include:

(a) by an alkylation reaction between "B" or precursor to "B" and the hydrocarbon chain moiety R and/or R', involving nucleophilic displacement of a good leaving group, followed by elaboration of "precursor to
20 B" if required. For example, O-alkylation by procedures analogous to those described by F. Fages et al., Bull. Soc. Chim. Fr., 959, 1985 or by Felgner et al., Proc. Nat. Acad. Sci., 84, 7413, 1987; N-alkylation by procedures adapted from A. Yamagishi, J. Phys. Chem.,
25 85, 281, 1981; J. Sonderrmann, Liebigs Ann. Chem., 749, 183-197, 1971; or S.M. Karesh, Ph.D. Dissertation, University of Maryland, 1975; S-alkylation by procedures adapted from R.A. Pascal, Jr. and D.L. Ziering, J. Lipid Res., 27, 221, 1986 or L.H. DeRiemer et al., J. Labelled Compds and Radiopharm., 18, 1517, 1981.
30

(b) by an acylation reaction between "B" or "precursor to B" and the hydrocarbon chain moiety R and/or R', followed by elaboration of "precursor to B", if required. For example, O-acylation to form an ester

linkage by procedures adapted from C.L. Penney et al.,
J. Org. Chem., 50, 1457, 1985 or A.W. Nicholas et al.,
Lipids, 18, 434, 1983; N-acylation to form an amide
linkage by procedures adapted from T.G. Wensel and C.F.
5 Meares in "Radioimmunoimaging and Radioimmunotherapy";
Burchiel, S., Rhodes, B.A., Eds.; Elsevier, New York,
1983, p. 1985 or S. Hirano and W. Ohashi, Carbo. Res.
59, 285-288, 1977.

(c) by an addition reaction between "B" or
10 "precursor to B" and the hydrocarbon chain moiety R
and/or R', involving an amino or hydroxyl function and
an isocyanate or isothiocyanate functionality, followed
by elaboration of "precursor to B" if required. For
addition reactions to isocyanates, see Satchell and
15 Satchell, Chem. Soc. Rev., 4, 231-250, 1975, and for
addition reactions to isothiocyanates, see Walter and
Bode, Angew. Chem. Int. Ed. Engl., 6, 281-293, 1967.

(d) by a condensation reaction between "B" or
"precursor to B" and the hydrocarbon chain moiety R
20 and/or R', involving an amino function and an aldehyde
functionality to give a Schiff base derivative, followed
by elaboration of "precursor to B" moiety, if required.
For example, see European Patent No. 0088695 A2 and
references cited therein.

25 Other suitable reaction schemes, including
variations or modifications of those just mentioned,
will occur to those skilled in the art.

Reaction schemes appropriate for the preparation of
specific classes of compounds useful in the practice of
30 this invention are as follows:

1. Fluorescent Compounds with Lipophilic Tails

Oxacarboyanine derivatives may be prepared as
shown in scheme 1 below. 2-Methylbenzoxazole

(commercially available) is alkylated with an alkyl iodide (R'I) as described by J. Sims et al., Biochemistry, 13, 3315-3330, 1974 to give (1) which is reacted further with N,N'-diphenylformamidine

5 (commercially available), by a method analogous to that described in U.S. Pat. 2,647,054, to give (2). Compounds (3) and (4) are prepared by the method of J. Sonderrmann, Liebigs Ann. Chem., 749, 183-197, 1971. Alcohol (ROH) is treated with 4-chlorobenzenesulphonyl

10 chloride (commercially available) to give (3) which is then reacted with 2-methylbenzoxazole to give (4). Intermediates (2) and (4) may be coupled together by refluxing in ethanol containing triethylamine (two equivalents) to yield oxacarbocyanine (5) (a

15 modification of the procedure described in U.S. Patent No. 2,647,054).

Acridine derivatives are prepared as shown in scheme 2 by a procedure analogous to the one described by A. Yamagishi et al., J. Phys. Chem., 85, 281, 1981.

20 4-Chlorobenzenesulphonate (6) is prepared by the procedure of J. Sonderrmann, Liebigs Ann. Chem., 749, 183-197, 1971, (see above), heated with acridine orange (7) (commercially available) and then treated with potassium iodide to yield acridinium iodide (8).

25 Suitable rhodamine B derivatives may be prepared as described by P.M. Keller et al., J. Cell. Sci., 28, 167-177, 1977. This procedure is illustrated in scheme 3 and involves esterification of rhodamine B (9) (commercially available) with a lipophilic alcohol

30 (ROH), via its acid chloride.

2. Metal Chelators with Lipophilic Tails

Scheme 4 illustrates two methods (a) and (b) for preparing aminopolycarboxylic acid-type chelators, e.g.,

ethylenediamine tetraacetic acid (EDTA), with lipophilic tails (R) which should be capable of complexing a wide range of metal cations.

Compound (12) may be synthesized by a procedure analogous to that described by W. C. Eckelman et al., J. Pharm. Sci. 64, 704, 1975. This procedure involves alkylation of diethylenetriamine (10) (commercially available) with an alkylbromide (RBr), followed by treatment with HBr to give (11). Intermediate (11) is then reacted with sodium chloroacetate to yield (12).

Another procedure involves synthesizing compound (13) from p-nitrophenylalanine (commercially available) as described by L. H. DeRiemer et al., J. of Labelled Compds. and Radiopharm., 18, 1517-1534, 1981, and coupling (13) with an acid chloride (RCOCl), as described by T. G. Wensel and C. F. Meares in "Radioimmunoimaging and Radioimmunotherapy," Burchiel, S., Rhodes, B.A., Eds.: Elsevier, New York, 1983, p. 185, to give product (14).

The synthesis of three chelators suitable for complexing with Technetium are illustrated in scheme 5. These may be derived from intermediate (15) which has been prepared from ethyl 2,3-diaminopropionate (See E. F. Godefoi, Chem. Abstr., 51:463; 1956) by S.M.N. Efange et al., J. Nuc. Med., 28, 1012-1019, 1987. Reaction of (15) with a lipophilic amine RR'NH would furnish (16) which upon acidic hydrolysis would then yield (17). Compound (17) may be converted to chelator (18) by a method analogous to that of S.M.N. Efange et al. (J. Nuc. Med., 28, 1012-1019, 1987) which involves treatment of (17) with 2,2'-dithio-bis(2-methylpropanal) (See H.F. Kung et al., J. Nuc. Med., 25; 326-332, 1984) followed by the simultaneous reduction of the

disulphide, the diimine and the amide with lithium aluminum hydride.

Alternatively, (17) may be converted to chelator (19) by a method analogous to that of R.O. Neirinx et al., J. Nuc. Med., 28, 191-202, 1987, which involves treatment of (17) with 2,3-butanedione monoxime (commercially available) followed by reduction of the diimine with sodium borohydride.

As another alternative, (17) may be converted to chelator (20) by a procedure analogous to that described in U.S. Patent 4,444,690, which involves reaction of (17) with chloroacetyl chloride followed by reaction with sodium thiobenzoate, after which cleavage of the benzoyl groups is effected with alkali.

15 3. Proteinaceous Substances with Lipophilic Tails

Four possible ways of attaching lipophilic tails to proteinaceous substances are described below.

(i) Via Cyanuric Chloride (trichlorotriazine)

This method is illustrated in scheme 6 and is analogous to the procedures described by C. W. Mahorey and A. Azzi, Biochem. J., 243, 569-574, 1987, and D. Blakeslee and M. G. Baines, J. Immuno. Meth., 13, 305-320, 1976. The lipophilic tail (R) is attached to cyanuric acid (commercially available) via nucleophilic displacement of one chlorine on cyanuric acid (21) by an alkyl amine, to give dichlorotriazinylaminoalkyl (22), this is then coupled to the protein to give (23) via another nucleophilic displacement of chlorine by an amino group on the protein.

30 (ii) Via Activated Esters

This method is illustrated in scheme 7 and is analogous to the procedure described by A. Huang et al., Biochimica et Biophysica Acta, 716, 140-150, 1982. The

activated ester (24) of an acid with a lipophilic tail, R, is formed and undergoes a nucleophilic displacement reaction at the ester carbonyl with the amino group of a protein. The activated ester may be

- 5 N-hydroxysuccinimide, trichlorophenol or p-nitrophenol and is usually formed by coupling of the acid and alcohol with dicyclohexylcarbodiimide.

(iii) Via Addition to Isothiocyanate

This method is illustrated in scheme 8 and is
10 analogous to the procedures described by Esteban et al., J. Nuc. Med., 28, 861, 1987 and C. F. Meares et al., Anal. Biochem. 142, 68-78, 1984. The lipophilic tail, R, is attached to the protein by the addition reaction of an amino residue on the protein to an isothiocyanate
15 functionality on the lipophilic moiety forming a thiourea linkage.

(iv) Via Schiff Base Formation

In the case of glycoproteins, the carbohydrate side chain may be selectively oxidized by chemical or
20 enzymatic means and the resulting aldehyde functionality reacted with a lipophilic amine to form a Schiff base derivative. The Schiff base derivative could then be reduced with sodium borohydride or sodium cyanoborohydride to form a more stable adduct if
25 required. This procedure would be analogous to the one described in European Patent 0088695 A2.

4. Carbohydrates with Lipophilic Tails

Syntheses of N-acetyl-D-neuraminic acid derivatives with lipophilic tails may be prepared by a procedure
30 analogous to that described by H. Ogura et al., Carbo. Res., 158, 37-51, 1986, as shown in scheme 9.

Compound (26), prepared by H. Ogura et al. from N-acetyl- -D-neuraminic acid (25) (from edible bird

nest) by reaction with acidic methanol and then acetyl chloride, may undergo a Koenigs-Knorr reaction with a lipophilic alcohol, ROH, to give (27) as a mixture of α and β anomers, which upon treatment with sodium
5 hydroxide to cleave the methylester and O-acetates should furnish lipophilic derivatives (28).


Suitable hexarin derivates may be prepared using a procedure analogous to that described by S. Hirano and W. Ohashi, Carbo. Res., 59, 285-288, 1977, which
10 involves reacting N-desulphated heparin with a lipophilic anhydride to give an N-acyl derivative.



15



20

25


30

SCHEME 1

SCHEME 2SCHEME 3


SCHEME 4

SCHEME 5




WO 89/10758
SCHEME 6


PCT/US89/00087









SCHEME 7



SCHEME 8



SCHEME 9

- 36 -

As previously noted, the nature of the hydrocarbon tails substituted on the compounds of the invention are important to the success of binding the bio-affecting moiety to the plasma membrane of the cell. In compounds having a single hydrocarbon tail, e.g., acridine derivatives, the linear number of carbons should be 23 or greater. In compounds having two or more hydrocarbon tails, one of the tails must have a linear length of at least 12 carbons, with the sum of the linear carbon atoms in the hydrocarbon tails being at least 23. The membrane retention coefficient should be at least 90. In other words, at least 90% of the compound being tested must be retained over a 24 hour period. The procedure for determining the membrane retention coefficient is exemplified hereinbelow.

20

25

30

As previously mentioned, the compounds of the invention must be capable of binding to the carrier cells without appreciable toxicity to the carrier cells.

5 To determine the extent of cytotoxicity, cells are exposed to a compound of the invention at a variety of concentrations, including zero concentration. The cells are then exposed to trypan blue or propidium iodide (Celada, F. and Rotman, B., Proc. Natl. Acad. Sci., 57,
10 630, 1967). These dyes are normally excluded by a living cell and only permeate the membrane of a dead cell. After the appropriate incubation time the cells are examined with a microscope or a flow cytometer and the percentage of stained cells (percent dead) is
15 determined. A compound is acceptable for the applications described herein, only if the cytotoxicity is less than 10% at the concentrations of compound used for cell binding. All the compounds specifically exemplified hereinbelow satisfy this criterion.

20 Binding of the compounds of the invention to carrier cells should also exert no appreciable detrimental effect on desired cell functions. Since the practice of this invention utilizes cells as carrier vehicles, it is important that binding of the compounds
25 of the invention to cells, does not alter cell functions which are important to their ability to perform as carriers. For example, it may be important for the labeled cell to divide in order for it to perform in a given application. On the other hand, the compound used
30 may alter some function having no effect on the division potential or other performance requirement of the cell for the contemplated application. Hence, such compounds may be considered to be without appreciable detrimental

effect on cell function for purpose of its use in this invention. Procedures are exemplified below for determining the effect on cell functions of potential importance to the practice of this invention, produced
5 by compounds of the invention.

Two criteria must be met in selecting a cell binding medium in order to reproducibly bind compounds of the invention to the plasma membrane of cells without diminishing cell viability or otherwise producing a
10 detrimental effect on desired cell function. The cell binding medium must (i) be at an iso-osmotic concentration as to not cause shrinkage or swelling and possible damage to the cells and (ii) allow for the compounds of the invention to be solubilized in such a
15 manner that they are available at consistent concentrations to incorporate into the plasma membrane of the cells.

As noted above, the compounds of the invention have a lipophilic nature which allows them to become embedded
20 into the plasma membrane of the cell and remain there in a stable manner. The very characteristics which allow the compounds of this invention to be used in cell labeling, namely, tendency to orient themselves preferably in the non-polar environment of the membrane
25 and not transfer via the surrounding ionic media to neighboring cells, creates the problem of the application of such compounds to the cells in a manner which allows for reproducible binding. Solubility time course experiments have shown that the compounds which
30 serve to stably label the plasma membrane when solubilized in ionic solutions, (e.g., phosphate buffered saline, culture medium, etc.) tend either to

form micelles or aggregates which can be precipitated. Consequently, the concentration of such compounds in a form adequate for binding to the plasma membrane is decreased and time dependent, thus resulting in reduced incorporation of the compound into the plasma membrane. Moreover, such binding as a results occurs in a non-consistent manner.

The iso-osmotic characterization of the binding medium may be performed using commercially available instrumentation (Osmette, Precision Instruments, Sudbury, Mass.). This instrumentation precisely measures freezing point depression of a given solution, which provides information as to the concentration or osmotic pressure of the solution. An iso-osmotic solution will support a given cell without having any effect on its volume. Osmolarities of solutions which will support mammalian cells normally range between 260 and 340 milliosmols. By these measurements the concentration of a given solution, which can be used to apply the compounds of this invention, can be adjusted such that an iso-osmotic solution is obtained. The binding medium should also be isotonic for the bioparticle to which the compound is to be bound.

The second criterion for selection of a suitable medium for binding of said compounds requires experimental evaluation of the actual stability of said compounds in a given medium and can be characterized by compound solubility determination (CSD). In making such determination, the compound is prepared in an ethanol stock at a concentration of $2 \times 10^{-3}M$. Ten milliliters of a working solution is prepared from the ethanol stock so that a final concentration of 1 to $4 \times 10^{-5}M$ is obtained. One milliliter of this solution

is then aliquoted into each of six 1.5 ml micro-centrifuge tubes. One tube is microfuged at 10,000 x g at time points equal to 0, 15, 30, 45, 60, and 120 minutes. A 100 ul aliquot is removed from the supernatant and diluted into 3.0 ml of ethanol for each time point sample. Fluorescent compound concentrations in the supernatants over the 2 hour time point can be determined by observing the fluorescence units obtained from a spectrofluorometer using the peak excitation and emission wavelengths for the compound of interest.

With radioisotopic compounds the same experimental procedure is applicable and the results can be determined by using beta or gamma counters. In all cases, the amount of the compound of the invention in the supernatant of said iso-osmotic solution at each time point is compared to a sample of such compound using ethanol as a solvent, which, although not suitable for labeling cells, serves to allow for the maximum compound solubility (total). The percent solubility of the compound is determined in each of the composition formulations, and is monitored over the 2 hour time course. Any composition formulation which shows more than a 20% deviation over the 2 hour time points will not provide for reproducible binding to the plasma membrane by the compound of interest.

Several factors enter into the determination of the concentration of the compound of the invention used to bind to the plasma membrane of cells. The intended effect to be produced by the compound, the cell type being labeled, and the method of detection are primary considerations. Using fluorescent compounds, for example, to follow cell growth or division, the highest concentration possible is desired which will not cause

quenching of said compounds and which will allow for a large dynamic range between labeled and non-labeled cell types. There is, however, an upper limit to the excessive incorporation of the compound into the plasma
5 membrane. Using tissue culture cells, concentration ranges from 1×10^{-6} M to 1×10^{-5} M allow for the monitoring of at least 6 cell divisions of the population while concentrations in excess of 4×10^{-5} M have been shown to produce some cytotoxic
10 effect on certain cell types being labeled.

With the radio-isotopic compounds different concerns must be addressed. Here the determination of the concentration of the compounds for application to the plasma membrane is primarily dependent on the
15 sensitivity of the method of detection and correspondingly the energy of the radio-isotope being used. The time required for labeled cells to reach their target site also becomes important and in the ideal situation a balance exists between all of these
20 factors. For diagnostic purposes, the goal is to incorporate enough of the radio-binding compound to allow for detection of the location of the labeled cells once they have reached the location of interest, while minimizing the amount of radiation exposure to the
25 patient. The half-life and the energy emitted by the radio-isotope being used, as well as the number of labeled cells necessary to image or diagnostically locate the site of interest, all concomitantly contribute to the optimum or minimum concentration for
30 cell binding.

Use of the compounds of the invention for therapeutic purposes involves concerns similar to those applicable to the fluorescent applications. The primary

goal is to incorporate as much of the therapeutic agent into the cell membrane as possible. By maximization of the incorporated therapeutic agent into the plasma membrane of the cell, fewer cells would be required to reach the desired location to exert the desired effect. Once again, the amount incorporated may only increase to such a level that no negative alterations are noted in the carrier cell with respect to viability or capability of the cells to migrate to the desired location.

Representative methods of use of the compositions of the invention will now be described with reference to particular diagnostic and therapeutic applications.

Cell Labeling With Fluorochrome

Fluorescent compounds of this invention are applied to carrier cells in the absence of serum and other lipid-containing materials. Cells are removed from the body or taken from culture and washed to be free of serum. They are suspended in a composition of the invention which includes the iso-osmotic regulating agent but not in ionic solutions and an appropriate concentration of the fluorescent compound (10^{-5} to 10^{-7} M). Binding of the compound to the cells is generally complete within ten minutes and the binding reaction is stopped with the addition of autologous or heterologous serum. The cells are then washed in serum containing media (5-10% v/v) and placed into culture or injected into the animal, depending on the application.

The procedure for cell binding of compounds of the type described herein is described in further detail in the aforementioned U.S. Patent application Serial No. 925,192, the entire disclosure of which is incorporated by reference in the present specification as though written out herein in full.

Another method involves suspension of the fluorescent compound in saline to allow for micelle formation. The cells are then placed into the resulting suspension and the phagocytic cells (for example, monocytes, macrophages and neutrophils) will preferentially become labeled. In this way, it is possible to selectively direct the stain to the phagocytic cells.

Binding of a fluorochrome to transplanted bone marrow cells in the manner just described allows the determination of whether the cells migrate to a specific site of hematopoiesis and, after detection at such site, whether cell division occurs there. A fraction of the donor's cells are subjected to density gradient sedimentation and the mononuclear cells are isolated, washed and labeled with the non-ionic application of fluorescent compound. The washed fluorescently labeled cells are injected into the recipient intravenously. At periodic intervals (2-4 hours) blood is removed by venipuncture and the percent of labeled cells is determined, e.g., using flow cytometry. The rate of disappearance of the cells from the circulation is a measure of the speed at which the cells are homing to centers of hematopoietic activity. Additionally, bone marrow aspirates are taken at weekly intervals and then subjected to density gradient sedimentation. The mononuclear population obtained by this method is then exposed to a "cocktail" of monoclonal antibodies which bind to myeloid cells and are labeled with a fluorescent color different from the tracking compound. Using monoclonal fluorescence and flow cytometry, it is then possible to determine the fluorescent intensity of the tracking dye on those cells which are of myeloid origin.

If the intensity of the tracking dye on the myeloid cells diminishes with time, then a growth rate can be determined for these cells. This procedure is described more fully in the aforementioned U.S. Patent application
5 Serial No. 925,445, the entire disclosure of which is incorporated by reference in the present specification as though written out herein in full. Furthermore, the fact that the cells are growing is of clinical significance to demonstrate that the transplanted marrow
10 is repopulating. Similar methods are used for evaluating other cell lineages, if desired.

Another application of the fluorescent-labeled cells is in chemosensitivity testing. After a primary tumor is excised, the cells are dispersed and labeled
15 with a fluorescent compound of the invention. The cells are then placed into wells and the fluorescence intensity of the cells is determined, e.g., by quantitative cytometry. As the cells divide, the fluorescence intensity will diminish and this loss of
20 fluorescence can be determined with a cytometer at various intervals after placing the cells in culture. The rate of loss of fluorescence in the presence or absence of varying concentrations of a chemotherapeutic drug is a measure of cytostasis caused by the drug.
25 Additionally, a dye exclusion test can be used simultaneously to determine the level of cytotoxicity. If the tracking dye is green fluorescing, then the red dye propidium iodide could be used for cytotoxicity measurements. Furthermore, it is possible to use
30 monoclonal antibodies which specifically bind tumor cells in combination with the dyes just described to monitor cytostasis and cytotoxicity on tumor cells and normal cells independently.

- 45 -

Fluorescent-labeled cells may also be used in monitoring the fate of transfused red blood cells to determine whether the patient is experiencing post-surgical bleeding, or whether there is an autoimmune hemolysis. To achieve this goal, an aliquot of the red cells to be transfused is labeled with the fluorescent form of the tracking dye. The fluorescent cells are transfused with the remainder of non-fluorescent cells and immediately post-surgery a blood sample is taken, e.g., by venipuncture. The percent fluorescent cells may be determined using flow cytometry or fluorometry. At periodic intervals additional blood samples are taken and the percent labeled cells is determined. If the patient is experiencing post surgical bleeding, the ratio of fluorescent to non-fluorescent cells will not change even though the hematocrit may be dropping. If the patient is experiencing autoimmune hemolysis, the ratio of fluorescent to non-fluorescent cells will drop because the antibody will be directed only against the transfused cells.

RADIO-IMAGING

The compounds of this invention which have the capacity of binding to the lipid phase of the membrane and to chelate Indium-111 or Technetium-99m, or other radio-imaging atoms, are first bound to the radioactive ion to form a stable complex. The complex is separated from the free radioisotope, then transferred to an iso-osmolar solvent that is non-ionic. The cells are placed together with the chelator-radioisotope complex in this solvent and the complex is then bound to the cell membrane. The binding reaction is stopped with autologous or heterologous serum. The cells (or viruses) are washed free of unbound chelator-

radioisotope complex and the cells (or viruses) are ready to be injected into the animal and the final location detected using a gamma camera.

Such compounds may be used to locate the site of
5 occult infection via binding to a neutrophil, the primary phagocytic leukocyte of the blood. When attempting to locate the site of occult infection in a symptomatic individual, leukocytes are isolated from the individual's blood. These cells are then labeled with
10 Indium or Technetium, generally as described above, and injected intravenously. Within the next 48 hours, the radioactive-labeled neutrophils migrate to the site of the infection where the gamma emission can be detected using a gamma camera.

15 In another application of this technology, a platelet may be tracked to the site of fresh plaque on arterial walls or to a thrombus. When attempting to locate the site of plaque formation in a symptomatic, or asymptomatic individual, platelets are isolated from the
20 individual's blood using standard gradient techniques. These cells are then labeled with Indium or Technetium, as described, and injected intravenously. A suitable procedure for binding compound of the type described herein to platelets is provided in the aforementioned
25 U.S. Patent application Serial No. 925,192. Within the next 48 hours, the radioactive labeled platelets migrate to the site of the plaque formation on arterial walls, where the gamma emission can be detected using a gamma camera.

30 In another application of the radio-imaging methodology described herein, a tumor infiltrating lymphocyte may be isolated from a primary lesion, expanded in Il-2, labeled with a tracking

radioisotopic form of a compound of the invention and the washed cells are injected intravenously. In this application, the assumption is made that a tumor infiltrating lymphocyte is at the tumor site because of an ability to detect the presence of tumor cells and then migrate to that site. Furthermore, the frequency of tumor tracking lymphocytes in circulation is very low, and by using the lymphocytes found in the primary tumor, advantage is taken of the body's own mechanism to concentrate these tracking cells. These cells are grown in the presence of a lymphocyte specific growth factor (Il-2) and in the presence of tumor cells. The in vitro growth of lymphocytes expands their number so that a portion of these cells is radioactively labeled and injected while the remainder is placed into dimethyl sulfoxide (DMSO) and serum and frozen at liquid nitrogen temperatures for preservation. These frozen cells can be thawed, radioactively labeled and injected periodically, and thereafter imaged using gamma imaging techniques to locate the position of metastatic lesions.

RADIO-ISOTOPE LABELING

While it is possible to use chelators to bind to radioactive metal ions, it is also possible to make fluorescent or non-fluorescent compounds of the formula $R-B-R_1$, wherein radio-isotopic atoms are constitutive to the molecule. For example, radioactive iodine, carbon, nitrogen, sulphur, phosphorus or selenium may be incorporated into the compounds of the invention. Compounds emitting gamma rays of sufficient energy may be detected using gamma scintigraphy. For these radionuclides, all of the applications discussed above under the heading radio-imaging can likewise be

- 48 -

accomplished. If the isotope is a low energy non-penetrating beta emitter, then the compound can be used in research applications using standard beta counting techniques.

5 MAGNETIC RESONANCE IMAGING

The compounds of this invention which have the capability of binding to the lipid phase of the membrane and to chelate Gadolinium or other MRI contrast enhancing agents, are first bound to the ionic species
10 of the selected metal to form a complex. The complex is separated from the free MRI contrast agents and then transferred to an iso-osmolar solvent that is non-ionic. The cells to be tracked are introduced into the solvent containing the chelator-ion complex, which becomes bound
15 to the plasma membrane of the cells. The binding reaction is stopped with autologous or heterologous serum and the washed cells are ready for use in magnetic resonance imaging applications. Compounds of the type just described enable detection of the site of occult
20 infection. When attempting to locate the site of occult infection in a symptomatic individual, leukocytes are isolated from the individuals' blood. These cells are then labeled with a chelator-gadolinium complex, as described, and injected intravenously. Within the next
25 48 hours, the contrast agent labeled neutrophils migrate to the site of the infection where they can be detected by magnetic resonance imaging.

In another MRI application of the invention, a platelet may be tracked to the site of fresh plaque on
30 arterial walls or thrombus. When attempting to locate the site of plaque formation in a symptomatic, or an asymptomatic individual, platelets are isolated from the

individual's blood using standard gradient techniques. These cells are then labeled with a chelator-gadolinium complex, as described, and injected intravenously. Within the next 48 hours, the contrast agent labeled
5 platelets migrate to the site of the plaque formation on arterial walls, where they can be detected by magnetic resonance imaging.

In another MRI application of the invention, a tumor infiltrating lymphocyte may be isolated from a
10 primary lesion, expanded in Il-2, labeled with a magnetic resonance sensitive isotope and injected intravenously. In this application, the assumption is made that tumor infiltrating lymphocytes are at the primary tumor site because of an ability to detect the
15 presence of tumor cells and that they are capable of migrating to the site of a metastasis. Furthermore, the frequency of tumor tracking lymphocytes in circulation is very low and by using the lymphocytes found in the primary tumor, use is made of the body's own mechanism
20 to concentrate these tracking cells. The cells grown in the presence of a lymphocyte specific growth factor (Il-2) and in the presence of tumor cells. The in vitro growth of lymphocytes expands their number so that a portion of these cells are isotopically labeled and
25 injected while the remainder are placed into DMSO and serum and frozen at liquid nitrogen temperatures for preservation. These frozen cells can be thawed, isotopically labeled and injected at many intervals after the initial growth period. The labeled tumor
30 infiltrating lymphocytes are then injected, whereby they migrate to the site of metastatic tumors and can be detected by magnetic resonance imaging.

ISOTOPIC THERAPEUTIC APPLICATIONS

The compounds of this invention which have the capability of incorporating into the lipid phase of the membrane and to chelate ions which are radioactive and
5 emit high linear energy transfer (LET) radiation, can be used to deliver radiation therapy to the site of disease. These chelators are first bound to the appropriate radioactive ion (e.g., ^{67}Cu , Yt, alpha
10 emitters) to form a complex. The complex is separated from the free ions and then transferred to an iso-osmolar solvent that is non-ionic. The cells to be used as therapeutic carrier vehicles are introduced into the solvent containing the chelator-ion complex, which becomes bound to the plasma membrane of the cells. The
15 binding reaction is stopped with autologous or heterologous serum, and the washed cells can be injected into the animal to track to the disease site for delivery of their radiation therapy.

In another application of this radiotherapeutic
20 delivery technique, a tumor infiltrating lymphocyte may be isolated from a primary lesion, expanded in Il-2, labeled with the radiotherapeutic complex and injected intravenously. This application also relies on the capability of tumor infiltrating lymphocytes to detect
25 the presence of tumor cells and then migrate to a metastatic site. These cells are grown in the presence of a lymphocyte specific growth factor (Il-2) and in the presence of tumor cells. The in vitro growth of
30 lymphocytes expands their number so that a portion of these cells are isotopically labeled and injected. The labeled cells track to the site of metastatic disease, and emit radiation which kills the metastatic tumor cells.

CELL TARGETING BY BINDING SPECIFIC PROTEINS TO CELL
MEMBRANES

In another embodiment, the compounds of the invention incorporate proteinaceous substances, including proteins, glycoproteins, lipoproteins or peptides as the bio-affecting moiety. These compounds are formulated containing the iso-osmotic regulator which is compatible with their solvation and cell viability. The cells are placed into the cell binding medium whereupon the hydrocarbon chains of said compounds become embedded into the plasma membrane and place the protein onto the surface of a specific cell type.

The procedure just described may be used to bind monoclonal antibody to human fibrin to the surface of a tracking cell, e.g., red cell. The antibody-bound red cell is then isotopically labeled, as described above, using the radio-imaging compounds or the magnetic resonance imaging compounds. This doubly labeled (anti-fibrin + isotope) cell may be injected into a patient whereby the cell migrates to the site of a fibrin clot and can be imaged using standard gamma scintigraphy or nuclear imaging.

In another application of this invention a monoclonal antibody to human cell surface tumor antigens may be bound to the surface of a tracking cell, e.g., monocyte or lymphocyte. The resultant cell is then isotopically labeled, as described above, using the radio-imaging compounds or the magnetic resonance imaging compounds. This doubly labeled (anti-tumor cell + isotope) cell is injected into a patient whereby the cell tracks to the site of a tumor and can be imaged using standard gamma scintigraphy or MRI.

In another application of this technology

(R-tPA-R₁) is applied to the surface of a tracking cell (e.g., red cell). The same cell is then isotopically labeled as described above using the radio-imaging compounds or the magnetic resonance imaging compounds. This doubly labeled (tPA + isotope) is injected into a patient whereby the cell tracks to the site of a fibrin clot and can be imaged using standard gamma scintigraphy or nuclear imaging. This same general protocol could be utilized without the addition of the isotope and administered to deliver more tPA to a fibrin clot site to produce a therapeutic action.

In another application of this invention, a monoclonal antibody which binds to human fibrin is bound (R-Mab-R₁) to the surface of a cell (e.g., red cell). The same cell is then also bound with a fibrinolytic compound (tPA, Streptokinase, urokinase) of the form (R-tPA-R₁, etc.). Thus, the monoclonal antibody increases the ability to bind to fibrin and after binding delivers a large number of therapeutic fibrinolytic compounds.

PROTEIN COUPLING TO CELLS FOR VACCINE

In another application of this invention, a protein, glycoprotein, lipoprotein or peptide to which antibody production is desired, is bound (R-protein-R₁) to the surface of a cell (e.g., red cell, monocyte). This cell is then injected in the presence or absence of adjuvant. The timing interval between injections will depend upon the nature of the antigen (protein) but generally 10 million cells may be injected each time at intervals of not less than two weeks.

Antibody levels to the antigen are monitored with

standard Elisa procedures. Cellular immune levels can be measured on immunizing cells.

ALTERATIONS IN MIGRATION PATTERNS BY MODIFYING CELL SURFACE

5 In another application of this technology, sialic acids (R-sialic acid- R_1) or glycosaminoglycans (R-glyamgly- R_1) can be placed onto the plasma membrane of a cell. The specific compound is placed into iso-osmotic media as described hereinabove. Red cells, 10 for example, are placed into the solution, resulting in binding of the compound to the plasma membrane. The reaction is stopped with the addition of serum, after which the cells are washed in saline containing medium and are ready for injection.

15 Red cells traverse the circulation and as immature cells they have a large amount of sialic acid on their surface. As the red cell ages, the amount of sialic acid per cell is reduced making it possible for the splenic and liver macrophages to recognize red cell 20 membrane antigens, thereby removing them from circulation. By appropriately increasing the amount of sialic acid into the membrane of a red cell, it may increase the life of the red cell in circulation. The ability to increase the lifetime of a red cell may be 25 advantageous for a transplant patient or for a patient with anemia. When bone marrow transplant patients receive the transplant, it is several weeks before they are capable of making their own red blood cells. By using this technology to prolong the lifetime of their 30 own red cells, the patient can be given several marrow transplants, if need be, without having bouts of anemia.

In the case of the anemic individual, the anemia

may result from a decrease in the lifetime of the red cell or a decrease in the rate of production of red cells. In either case, to increase the lifetime of the red cell will reduce the anemia.

5 DELIVERY OF PHOTODYNAMIC COMPOUNDS FOR THERAPEUTIC ACTION

Photodynamic therapy for the cure of cancer is an area of intense research (Proceedings of SPIE-The International Society for Optical Engineering; Volume 10 847, "New Directions in Photodynamic Therapy", Douglas C. Neckers, Editor; October 1987). Many of these compounds are of the phthalocyanine class or the hematoporphrin class. All absorb light in the 600-800 nm region and produce excited state oxygen in the 15 process. According to existing protocols, the compounds are administered orally or parenterally and the specificity of binding to tumor cells is totally dependent upon the chemistry of each specific molecule. Once delivered to the tumor cell, the compounds are 20 excited with light whereby excited state oxygen is produced and the tumor cells are killed.

Using the methodology of this invention, a derivative of the compound (R-Photodynamic compound-R₁) is made and then dissolved in the 25 iso-osmotic solution. Tumor tracking cells (e.g., tumor infiltrating lymphocytes) are labeled with these compounds and the cells are injected into the patients. The tumor tracking cells then migrate to the site or the micrometastasis. Within 48 hours the patient is exposed 30 to high intensity light in the region where the photodynamic molecule absorbs and the excited state oxygen produced will kill the tumor cells. Furthermore, the tracking cell will be killed and this should

generate an inflammation whereby more immune cells converge to remove the dead cells, increasing the toxicity to tumors. In this method of delivery of photodynamic action, the tracking cells are responsible for the specificity of tumor kill.

The following examples are provided to describe the invention in further detail. These examples are intended to illustrate certain aspects of the invention and should in no way be construed as limiting the invention.

Example 1

Determinations of Effects Produced On Cell Function By Binding Of Compounds to Plasma Membrane

a. Effect On Growth Rate Of Cells

To measure the effect of compounds of the invention on cell growth rate, cells must be first exposed to varying concentrations of a selected compound.

To this end, logarithmically growing Yac-1 cells were washed once in PBS and resuspended in a solution of the fluorochrome 3,3'-ditetradecyloxacarbocyanine (DiO-Cl4(3)) ($10^{-5}M$) at a concentration of 10^6 - 10^7 cells/ml for 5 minutes at room temperature. The binding reaction was terminated by adding an equal volume of fetal calf serum (FCS) and the cells were pelleted at 400x g for 5 minutes, washed (3x) and resuspended in complete media. Fluorescence intensity measurements were made using a Coulter EPICS 753 flow cytometer. 200 mW of 488 nm light was used to excite the dye and the green fluorescence of propidium iodide negative cells was measured using a 525 nm band pass interference-type filter.

In Figure 1, the fluorescence intensity of YAC-1

cells stained with the DiOC₁₄(3), recorded in Figure 1, is extremely bright as compared with the unstained controls. Similar results have been obtained with other fluorescent compounds of this invention. A large
5 dynamic range between fluorescence positive and fluorescence negative cells is shown in Figure 1A. The range of the staining reaction is so large that the fluorescence intensity must be plotted on a semi-logarithmic scale.

10 To monitor the growth rate of cells, DiO-C14-(3) bound cells were placed into the incubator in complete culture media (DMEM High Glucose + 20% FBS) and analyzed daily using flow cytometric techniques. The instrument was aligned daily and intensity settings reproduced
15 using fluorescent microbead standards. From each fluorescence profile the mean fluorescence intensity and standard deviation were determined. A decrease in the fluorescence intensity is observed as a result of these determinations (Figure 1B).

20 In Figure 2, growth rates are compared for stained and unstained YAC-1 cells. Separate flasks of DiO-C14-(3) labeled and non-labeled control cultures (Yac-1) were each set at 2×10^5 cells/ml at time zero. Cell counts were obtained using a Coulter ZBI
25 cell counter (Coulter Electronics, Inc. Hialeah, Fl). Fluorescence intensity measurements were determined as described above with reference to Figure 1. Mean log fluorescence intensities were determined for each time point and the inverse was calculated and plotted.

30 Standard deviations were calculated and plotted at each time point having been determined on quadruplicate samples because cell growth kinetics are exponential in nature, a semilog plot of the fluorescence intensity is

linear during the log phase of growth as shown in Fig. 2. As can be seen from Figure 2, the growth rate is the same for stained and unstained cells. Furthermore, each day the average fluorescence intensity was determined for the stained culture. The inverse of the fluorescence intensity is plotted alongside the cell growth data in Figure 2 and it is clear that in a logarithmically growing culture, the decrease in fluorescence intensity is directly proportional to the cell growth rate.

b. Effect On Binding Affinity For Target Cells

Another cell function which is important in certain applications of the invention is the ability of a lymphocyte (NK-cell) to recognize, bind to and kill a target tumor cell. In a number of embodiments of this invention it is desirable to track an effector NK-cell to the site of a tumor. To determine if a compound of this invention has any detrimental effect on this function, effector cells or target cells are bound with the compound.

The standard assay for cell mediated cytotoxicity (Brunner, K. T., Maue, J., Cerottini, J. C., Chapuis, B., Immunol., 14, 181, 1968) is to label the target cells with ^{51}Cr and wash the cells free of all unbound ^{51}Cr . The effector cells are placed in contact with the target cells at varying ratios and when the target cells are killed by the effector cells, the ^{51}Cr is released from the cell into the medium. The level of cytotoxic kill is correlated to the amount of ^{51}Cr released into the medium, as determined by a gamma counter. To determine the affect of the compounds of this invention on cell mediated cytotoxicity, the

Cr⁵¹ release is measured for unlabeled cells, labeled effector cells and labeled target cells. The results of such measurements using DiOC14(3) labeled and unlabeled Yac-1 targets is shown in Figures 3 and 4.

5 Values for effector/target ratios of 50:1, 25:1, 12:1 and 6:1 of both Poly I:C and saline treated effectors to unstained Yac-1 targets are represented on the x-axis. Values of % kill for the same ratios of Poly I:C and saline treated effectors to stained Yac-1 targets are

10 represented on the y-axis. Ninety-five percent confidence intervals are represented by the dashed lines. From Figure 3, it can be seen that chromium release (% cytotoxicity) is the same whether the targets are stained with DiOC14(3) or unstained. Values for %

15 kill by Cr(51) release calculated for DiO-Cl4-(3) labeled Yac-1 targets and non-labeled Poly I:C treated NK-preps are represented on the x-axis. The percent kill by chromium release given on the y-axis represent values obtained using non-stained Yac-1 targets and

20 DiO-Cl4-(3) stained Poly I:C treated NK-preps. Samples were taken at times of 1, 2, 3 and 4 hours for both sample sets. E/T ratios used were 50, 25, 12, 6, 3, and 1.5 to 1. Figure 4 shows that the chromium release (% cytotoxicity) is the same whether the target cells or

25 the effector cells are stained. These results indicate that the function of cell mediated cytotoxicity is unchanged after labeling either effector or target cells with the fluorochrome.

The above described cell mediated cytotoxicity

30 assay demonstrates that the cell labeling does not affect the ability of the effector cell to find, bind or kill the target cell. It is possible that some other function not tested may be affected, but since the

functions of interest were unaffected, it may be concluded that there were no appreciable adverse effects on the function of cell mediated cytotoxicity.

Example 2

5 Determination Of Membrane Retention Coefficient

The membrane retention coefficient (MRC) provides information regarding how well a given compound is retained in the plasma membrane of a carrier cell and is
10 determined as described below.

Generation of red blood cell ghosts for use as a model membrane is achieved by centrifuging whole blood at 300 x g for 15 minutes, removal of the plasma and resuspension of the cell pellet in 0.83% (weight to
15 volume) ammonium chloride. The ghosts are pelleted from the ammonium chloride by centrifuging at 10,000 x g for 10 minutes. This ammonium chloride washing procedure is repeated a minimum of five times to insure that complete release of hemoglobin from the cells has occurred. The
20 ghosts are labeled with the compound in question at a concentration allowing for detection of the labeled ghosts by instrumental analysis or fluorescent microscopic methods, and at a concentration which would be used to label cells for a specific application as
25 described above. For these determinations stock solutions of the compounds in question are prepared in ethanol at a molar concentration of 2×10^{-3} , and working dilutions of the compounds were prepared in iso-osmotic sucrose (52 grams/500 milliliters distilled
30 water). After incubation of the ghosts at an approximate concentration of 1×10^9 ghosts/ml in the working dilutions of the compounds for 10 minutes, the samples are centrifuged at 10,000 x g to pellet the

ghosts and the staining solution was aspirated from the samples. The labeled ghosts are resuspended in 1 ml of phosphate buffered saline solution containing 10% fetal bovine serum (PBS-FBS). Triplicate 20 ul aliquots are removed from each sample for the determination of the amount of total compound present. The samples are centrifuged as described above and triplicate 20 ul aliquots are removed from the supernatant for quantitative determination of amount of compound present.

After sampling, the supernatant is aspirated and the red cell ghost pellet is resuspended in 1.0 ml of the PBS-FBS, which is once again sampled as described above. This procedure is repeated at least six times, allowing for detection of rapidly released compounds and is monitored after times equal or greater than 24 hours to allow for the detection of more slowly released compounds. For the determination of the amount of compound present in each sample, the 20 ul aliquots are extracted into 3.0 ml of n-butanol by shaking. The samples are centrifuged at 3000 x g to remove membrane debris and the butanol fractions are assayed for compound concentration. Fluorescent compounds are assayed in this manner using peak excitation and emission wavelengths for the particular compounds being assayed to determine the fluorescence units for each sample. Radiolabeled compounds do not require butanol extraction and could be assayed directly using beta or gamma counting instrumentation.

The determination of the amount of compound present in each sample as described above allows for the calculation of the MRC for each washing or fixed time point. The value is obtained by the following

formula:

$$((C_T - C_S) / C_T) * 100$$

where C_T represents the amount of compound present (in units determined by the method used to assay the compound) in the total sample and C_S represents the amount of compound present in the supernatant sample for that particular time point. The comparison of the MRC values defines criteria for identification of the compounds of this invention, these criteria being: 1) the MRC values determined for each washing steps should have a value of at least about 90 and 2) the percent difference between MRC values over at least a 24 hour time period should be less than about 10%. The data provided in Table I below are the results from one experiment and serve as an example of the MRC determination.

20

25


30

TABLE I
MEMBRANE RETENTION COEFFICIENTS (MRCs) FOR CELL BINDING COMPOUNDS


COMPOUND	WASH 1	WASH 2	WASH 3	WASH 4	WASH 5	WASH 6	24HR	CHANGE IN MRC
DiI-C5-3	51.63	51.12	44.82	41.39	12.59	17.48	0.00	100.00%
DiI-C10-3	83.28	92.36	94.63	94.94	95.33	94.80	54.08	42.95
DiI-C14-3	94.85	97.24	98.40	98.64	98.43	99.12	93.90	5.26
PKH/CMPD 1	50.40	61.20	64.45	65.85	70.62	77.92	18.84	75.82
PKH/CMPD 2	90.69	94.74	96.28	96.74	96.41	97.17	53.81	44.62
PKH-3	88.82	93.94	95.15	95.26	94.51	96.64	36.77	61.64
PKH-4	94.42	96.96	98.03	97.93	97.92	98.34	96.90	1.46
PKH-5	91.70	97.22	97.97	98.24	98.09	98.40	90.10	8.43
PKH-6	94.69	98.24	98.32	98.78	98.96	99.73	97.65	2.08
PKH-7	94.07	96.99	98.66	98.39	98.82	97.56	87.24	10.57
PKH-8	97.35	98.47	98.16	98.99	99.01	99.46	97.90	1.56
PKH-10	97.90	98.89	98.90	99.18	99.09	99.22	96.82	3.12
PKH-11	91.01	95.12	95.82	96.42	96.27	97.01	42.88	55.79
PKH-13	95.97	97.51	98.32	98.48	98.71	98.88	98.27	0.61

Structures for the above compounds identified in Table I are set forth in Table II.


TABLE II




PK11/CMPD-1




PKH-5




PKH/CMPD-2




РКН-6




РКН-3



PKH-7




РКН-4




РКН-8


TABLE II (Cont'd)




PKH-10




PKH-11




PKH-13



Dil-C5-(3)



Dil-C10-(3)



Dil-C14-(3)

Another procedure which may be employed to determine the cell binding capability of fluorescent compounds according to this invention is intercellular compound transfer analysis (ICTA). In performing this analysis, tissue culture cells, in this example Yac-1 cells, at a concentration of approximately $1 \times 10^7/\text{ml}$ are labeled with 4×10^{-6} M of the compound of choice in iso-osmotic sucrose solution for 10 minutes. Staining was terminated with an equal amount of FBS and the cells were washed three times and resuspended in complete tissue culture media. Equal numbers of labeled and non-labeled Yac-1 cells were placed into culture flasks at a density of 4×10^5 cells/ml in 20 ml of fluid. The cells were cultured for 4 days at 37°C in a 5% CO_2 atmosphere. An aliquot of each culture to be tested is removed daily for flow cytometric analysis. Percent labeled and fluorescence intensity was determined. The exciting and detection wavelengths for analysis are selected on the basis of the individual properties of the compound being tested.

A fluorescence histogram was generated for each of three test compounds and examples of such histograms are seen in Figure 5. Initially, each histogram contains two populations: the left most population represents the non-labeled cells which were added into the culture, and the right hand population represents the compound labeled cells of the culture. If the labeled and non-labeled cells are placed in culture at a 1:1 ratio the percentage of cells represented in either of the peaks should be approximately 50%. It is important to monitor three attributes of the histograms over time: 1) the mean intensity of the positive or labeled population, 2) the mean autofluorescence

intensity of the non-labeled population and 3) the percentage of positive or labeled cells in the culture. These three parameters serve to define whether the compound is stably retained in the membrane, thereby not transferring to other cells and serve to determine if the compounds produce a cytostatic and/or cytotoxic effect upon the cells to which they are bound. If transfer or leakage of the compound occurs, an increase in the mean intensity of the non-labeled population will be observed. In Figure 5A, it is noteworthy that on Day 1, the fluorescent intensity of non-labeled cells (left peak) was significantly increased over Day 0, indicating that (PKH-3) leaks out of labeled cells (right peak, Day 0) and becomes incorporated into unlabeled cells. In Table I above, a percent change in MRC of 61% for this same compound is also indicative of cell leakage.

On the other hand, if the leakage rate is substantial a merging of the non-labeled and labeled populations will occur (Fig. 5B). If a cytostatic and/or cytotoxic effect has occurred the percentage of the labeled population will decrease from the value determined at time zero. Figure 5B shows that the fluorescent intensity of non-labeled cells (left peak) is significantly increased over Day 0, indicating that 3,n-propyl-3'n-tetradecyloxcarbocyanine iodide (PKH/CMPD-1) leaks out of labeled cells. This is further evidence by a single peak on Day 2. Similarly, in Table I above, a percent change in MRC which of 76% for this same compound, is likewise of indicative cell leakage.

Fluorescent compounds usable in this invention have the following characteristics: 1) the percentage of cells in the labeled population over time does not significantly differ from the value obtained at time

zero, 2) the mean intensity of the non-labeled population does not significantly increase over time, and 3) the mean intensity of the labeled population decreases in a manner which correlates with the growth characteristics of the cells. 3-n-propyl-3'-n-docosanyloxacarbocyanine iodide satisfies these criteria, as is evidenced by the histogram of Figure 5C. Particularly noteworthy in Figure 5C is the total separation of stained and unstained cell peaks for the five days of the experiment. Furthermore, the percent stained did not change appreciably. From Table 1 above, a percent change in MRC of 1.46% is reported for this compound indicating very stable binding to the plasma membrane. Additionally, the fluorescence intensity of labeled cells decreased daily as the cells divide.

The MRC values set forth in Table 1, above, show excellent correlation with the results obtained from intracellular compound transfer analysis, as described herein.

20

25

30

Example 3

Preparation of Compounds

a. 3-n-propyl-3'-n-eicosanyloxacarbocyanine Iodide
3-n-propyl-2-methylbenzoxazolium iodide was
5 prepared according to the method described by J. Sims et
al., Biochemistry, 13 (16) 3315-30 (1974)

A stirred mixture of the 3-n-Propyl-2-methyl-
benzoxazolium iodide (9.09 g, 30 mmol) and
N,N'-diphenylformamidine (5.88 g, 30 mmol) in acetic
10 anhydride (60 ml) was heated under reflux for 30 mins.
The solution was then allowed to cool to room
temperature, diluted with ether (300 ml) and
refrigerated. The crystalline solid 2-(β
acetonilido)vinyl-1-benzoxazolium-n-propyliodide was
15 collected by filtration and recrystallized from
ethanol/ether to give a brown crystalline solid (4.77 g,
35%), m.p. 209-210°C. Found, C, 53.58%; H, 4.81%, N,
6.26%. $C_{20}H_{21}O_2N_2I$ requires C, 53.58%; H,
4.72%; N, 6.25%. ν_{max} ; 3100-3000, 3000-2800, 1721, 1616,
20 1589, 1217, 763 and 700 cm^{-1} . $^1H_{nmr}$, δ , 9.75 (d,
J=14Hz, 1H); 7.84-7.45 (m, 9H); 5.44 (d, J=14Hz, 1H);
4.49 (t, J=7Hz, 2H); 2.12 (s, 3H); 0.868 (t, J=7.4Hz,
3H).

To a stirred solution of eicosanol (5.0 g, 16.70
25 mmol) and triethylamine (4 ml) in methylene chloride (80
ml) was added dropwise a solution of 4-chlorobenzene-
sulphonyl chloride (3.90 g, 18.50 mmol) in methylene
chloride (20 ml) and this solution was stirred for 24 h.
The reaction mixture was then diluted with more
30 methylene chloride (100 ml) and washed with water (2 x
75 ml). The organic layer was dried over $MgSO_4$,
filtered and concentrated to give a crude product which
was recrystallized from methanol to give n-eicosanyl-
4-chlorobenzenesulphonate the product (5.10 g, 65%) m.p.

69-70°C. max; 3000-2800, 1367, 1184, 1176, 963
cm⁻¹. m/z, 472 (M⁺). Found C, 66.16%; H 9.75%;
S, 6.74%; Cl, 7.40% C₂₆H₄₅O₃SCl requires C,
66.00%; H, 9.59%; S, 6.78%; Cl, 7.49%. ¹Hnmr ,
5 0.855 (t, J=6.6Hz, 3H); 1.10-1.65 (m); 4.030 (t,
J=6.4Hz, 2H); 7.48-7.53 (m, 2H); 7.80-7.84 (m, 2H).

A stirred solution of 2-methylbenzoxazole (1.35 g,
10.10 mmol) and n-eicosanyl-4-chlorobenzenesulphonate
(4.00 g, 8.50 mmol) was heated at 130-135°C for 24 h.
10 After cooling, the solid formed was triturated with
ether and washed 2 more times with ether. The product,
3-n-eicosanyl-2-methylbenzoxazolium-4-chlorobenzene-
sulphonate, (4.20 g, 82%, m.p. 128-132°C) was allowed to
air dry and used without further purification in the
15 next step. ν max; 3000-2800, 1593, 1582, 1219, 1207,
1086, 1030, 1007, 824, 754 cm⁻¹. ¹Hnmr δ , 0.87
(m, 3H); 1.10-1.95 (m); 3.20 (s, 3H); 4.62 (t, J=7.5Hz,
2H); 7.12-7.72 (m, 8H). ¹³C nmr δ , 168.1, 147.8,
144.5, 135.1, 129.6, 128.8, 127.9, 127.3, 114.1, 112.9,
20 47.9, 31.8, 29.6, 29.4, 29.3, 29.0, 28.1, 26.6, 22.6,
13.9. Found m/z (M⁺) 414.3764 C₂₈H₄₈NO
requires 414.3736.

A solution of 2-(β -acetoniliodo)vinyl-1-benzo-
xazolium-n-propyl iodide (0.448 g, 1.00 mmol) and
25 3-n-eicosanyl-2-methylbenzoxazolium-4-chlorobenzene-
sulphonate (0.605 g, 1.00 mmol) in ethanol (15 ml) was
heated to dissolve the salts and then triethylamine
(0.40 ml) was added and the mixture heated at reflux for
1 h. The solution was then cooled and 15 ml of
30 saturated KI solution was added. The solution was then
diluted with water (150 ml) and extracted with methylene
chloride (150 ml). The methylene chloride layer was
washed with water, dried over MgSO₄, filtered and

- 70 -

concentrated to give a dark red gum which was crystallized from ethyl acetate to give brick red crystals of the desired product (0.42 g, 58%) m.p. 179-180°C. ν max: 3100-2800, 1564, 1506, 1211, 739 cm^{-1} . $^1\text{Hnmr}$ δ , 0.842 (t, $J=7\text{Hz}$, 3H); 1.062-1.454 (m), 1.859-1.999 (m); 4.226 (t, $J=7.4\text{Hz}$, 4H); 6.78 (d, $J=13.2\text{Hz}$, 1H); 6.80 (d, $J=13.2\text{Hz}$, 1H); 7.237-7.460 (m, 8H); 8.45 (t, $J=13.2\text{Hz}$, 1H). Found C, 66.22%; H, 8.21%; N, 3.79% $\text{C}_{40}\text{H}_{59}\text{O}_2\text{N}_2\text{I}$ requires C, 66.10%; H, 8.18%; N, 3.85%.

b. 3-n-pentyl-3'-n-octadecyloxacarbocyanine Iodide

A stirred solution of 2-methylbenzoxazole (10 g, 75 mmol) and n-pentyl iodide (14.85 g, 75 mmol) was heated at reflux for 18 h. After cooling, the yellow-brown solid was slurried in ether, filtered off and washed with ether. The resulting solid was air dried to give 3-n-pentyl-2-methylbenzoxazolium iodide (20.3 g, 82%).

A stirred mixture of 3-n-pentyl-2-methylbenzoxazolium (6.62 g, 20 mmol) and N,N'-diphenylformamidine (3.92 g, 20 mmol) in acetic anhydride (40 ml) was heated under reflux for 30 mins. The solution was then allowed to cool to room temperature, diluted with ether (200 ml) and refrigerated overnight. The crystalline solid, 2-(α -acetonilido)vinyl-1-benzoxazolium n-pentyl iodide, which formed was filtered off washed with ether several times and air dried (5.88 g, 62%).

3-n-octadecyl-2-methylbenzoxazolium-4-chloro-benzene-sulphonate was prepared according to the procedure described by J. Sandermann, Liebigs Ann. Chem. 749, 183, 197 (1971).

The 3-n-pentyl-3'-n-octadecyloxacarbocyanine iodide was prepared following essentially the same procedure used in Example 4a, with the following amounts of

reagents: 2-(β -Acetonilido)vinyl-1-benzoxazolium n-pentyl iodide (0.476 g, 1 mmol), 3-n-octadecyl-2-methylbenzoxazolium-4-chlorobenzene sulphonate (0.578 g, 1 mmol), triethylamine (0.40 ml) and ethanol (15 ml).

- 5 The dark red crude product was recrystallized from ethyl acetate to give (0.45 g, 62%) m.p. 170-173°C. ν max: 3100-2800; 1565, 1507, 1209, 739 cm^{-1} . $^1\text{Hnmr}$ δ , 0.86-0.94 (m, 6H); 1.24-2.00 (m); 4.28 (t, $J=7.1\text{Hz}$, 4H); 6.83 (d, $J=13.4\text{Hz}$, 2H); 7.26-7.48 (m, 8H); 8.49 (dd, $J=13$ and 13.2Hz , 1H). Found C, 66.39%; H, 8.13%; N, 3.79%; $\text{C}_{40}\text{H}_{59}\text{N}_2\text{O}_2\text{I}$ requires C, 66.10%; H, 8.18%; N, 3.85%.
- 10

c. 3-n-octyl-3'-n-octadecyloxacarbocyanine Iodide

- A stirred solution of 2-methylbenzoxazole (10.0 g, 75 mmol) and n-octyl iodide (18.0 g, 75 mmol) was heated at reflux for 18 h. After cooling, the yellow-brown solid was slurried in ether, filtered and washed with ether. The resulting solid was air dried to give (20.5 g, 73%) of 3-n-octyl-2-methylbenzoxazolium iodide.
- 15

- 20 A stirred mixture 3-n-octyl-2-methylbenzoxazolium iodide (7.46 g, 0.02 mol) and N,N'-diphenylformamidine (3.92 g, 0.02 mol) in acetic anhydride (40 ml) was heated under reflux for 30 mins. The solution was then cooled and placed under high vacuum for 48 h. The crude product was then dissolved in methylene chloride, washed with water (2 x 50 ml), dried over magnesium sulphate, filtered and concentrated to give 2-(β -acetonilido)vinyl-1-benzoxazolium n-octyl iodide as a crude product which was used without purification in the next reaction.
- 25
- 30

A solution of 2-(β -Acetonilido)vinyl-1-benzoxazolium-n-octyl iodide (1.11 g) thus obtained and 3-n-octadecyl-2-methylbenzoxazolium 4-chlorobenzene

5 sulphonate, prepared as described in Example 4b, (0.86 g, 1.50 mmol) in ethanol (20 ml) was heated to dissolve the salts and then triethylamine (0.60 ml) was added and the mixture heated at reflux for 1 h. The solution was cooled and 15 ml of saturated KI solution was added. The solution was then diluted with water (150 ml) and extracted with methylene chloride (150 ml). The methylene chloride layer was washed with water, dried over MgSO_4 , filtered and concentrated and the dark red
10 gum flash chromatographed on silica gel eluting with 5% methanol in CH_2Cl_2 . The desired product was recrystallized from EtOAc to give (0.58 g, 50%) m.p. 166-167°C. ν max; 1567, 1509, 1205, 739 cm^{-1} . $^1\text{Hnmr}$ δ , 0.838-0.881 (m, 6H); 1.901-1.956 (m, 4H)
15 4.277 (t, $J=6.5\text{Hz}$, 4H); 6.785 (d, $J=13.1\text{ Hz}$, 2H) 7.271-7.480 (m, 8H); 8.50 (t, $J=13\text{Hz}$, 1H) m/z, 641 (M+). Found C 67.37%, H 8.51%, N 3.63%; $\text{C}_{43}\text{H}_{65}\text{N}_2\text{O}_2\text{I}$ requires C 67.17%; H 8.52%; N 3.64%.

20 d. 3-n-propyl-3'-n-docosanyloxacarbocyanine Iodide
To a stirred solution of docosanol (6.0 g, 18.00 mmol) and triethylamine (4 ml) in methylene chloride (80 ml) was added dropwise a solution of 4-chlorobenzenesulphonyl chloride (4.26 g, 20.00 mmol) in methylene
25 chloride (100 ml) and this solution was stirred for 24 h. The reaction mixture was then diluted with more methylene chloride (100 ml) and washed with water (2 x 75 ml). The organic layer was dried over MgSO_4 , filtered and concentrated to give a crude product which
30 was recrystallised from methanol to give n-docosanyl-4-chlorobenzenesulphonate (5.8 g, 65%) m.p. 74-75°C. ν max; 3000-2800, 1367, 1185, 1177, 963 cm^{-1} . $^1\text{Hnmr}$ δ , 0.879 (m, 2H); 1.185-1.574 (m); 4.054 (t, $J=6.6\text{Hz}$, 2H); 7.53 (d, $J=8.8\text{Hz}$, 2H); 7.845 (d, $J=8.8\text{Hz}$, 2H).

m/z, 499 (M-H)⁺. Found C, 67.13%; H, 10.13%; S, 6.36%; Cl, 7.26%; C₂₈H₄₉O₃SCl requires C, 67.10%; H, 9.85%; S, 6.40%; Cl, 7.07%.

A stirred solution of 2-methylbenzoxazole (0.665 g, 5 mmol and n-docosanyl-4-chlorobenzenesulphonate (2.5 g, 5 mmol) was heated at 130-135°C for 24 h. After cooling, the solid formed was triturated with ether and washed 2 more times with ether. The product 3-n-docosanyl-2-methylbenzoxazolium 4-chlorobenzene-sulphonate, (1.80 g, 56%) m.p. 115-118°C was allowed to air dry and used directly in the next reaction. ν max: 3100-3000, 1595, 1582, 1220, 1198, 1086, 1032, 1008, 829, 756 cm⁻¹. ¹Hnmr δ , 0.88 (m, 3H); 1.10-1.95 (m); 3.26 (s, 3H); 4.73 (t, J=7.4Hz, 2H); 7.17-7.76 (m, 8H). ¹³Cnmr δ , 168.2, 147.8, 144.6, 135.0, 129.6, 128.7, 127.95, 127.9, 127.3, 114.1, 112.96, 47.9, 31.8, 29.6, 29.4, 29.3, 29.0, 28.1, 26.6, 22.6, 14.1, 14.0. Found m/z (M⁺) 442.4056 C₃₀H₅₂NO requires 442.4049.

The 3-n-propyl-3'-n-docosanyloxacarbocyanine iodide was prepared following essentially the same procedure used in Example 4a, with the following amounts of reagents: 2-(α -Acetonilido)vinyl-1-benzoxazolium-n-propyl iodide (0.45 g, 1 mmol), 3-n-docosanyl-2-methylbenzoxazolium 4-chlorobenzene-sulphonate (0.633 g, 1 mmol), triethylamine (0.40 ml) and ethanol (15 ml). The dark red crude product was crystallized from hot ethyl acetate to give brick red crystals of the product (0.45 g, 60%) m.p. 182-184°C. ν max: 3100-2800, 1565, 1507, 1209, 739 cm⁻¹. ¹Hnmr δ , 0.879 (t, J=6.3Hz, 3H); 1.105-2.049 (m); 4.264 (t, J=7.1Hz, 4H); 6.85 (d, J=13Hz, 1H); 6.86 (d, J=13.1Hz, 1H); 7.258-7.485 (m, 8H); 8.488 (dd, J=13.0 and 13.2Hz, 1H). Found C,

67.29%; H, 8.47%; N, 3.74%; $C_{42}H_{63}N_2O_2I$
requires C, 66.83%; H, 8.41%; N, 3.71%.

e. 3,6-bis (dimethylamino)-10-n-hexacosanyl
acridinium Iodide

5 A solution of hexacosanol (250 mgs, 0.654 mmol),
triethylamine (125 ml, 0.900 mmol) and
4-chlorobenzenesulphonyl chloride (150 mgs, 0.711 mmol)
in methylene chloride (30 ml) is stirred at room
temperature for 120 h. The reaction mixture is then
10 diluted with methylene chloride (20 ml) and washed with
water (2 x 50 ml). The organic phase is dried over
magnesium sulphate, filtered and concentrated to give a
crude product. Flash column chromatography on silica
gel (10:1 hexane:ethyl acetate) followed by
15 recrystallization from methanol gives
n-hexacosanyl-4-chlorobenzenesulphonate (80 mgs, 22%).

V_{max} : 3000-2800; 1367; 1185; 1177; 963; 831;
822 cm^{-1} . 1H nmr δ , 7.853 (d, $J=8.7Hz$, 2H); 7.533
(d, $J=8.6Hz$, 2H); 4.06 (t, $J=6.5Hz$, 2H); 0.887
20 (t, $J=6.3Hz$, 3H).

A solution of acridine orange (free base, 75% dye
content) (71 mgs, 0.200 mmol) and n-hexacosanyl-4-
chlorobenzenesulphonate (110 mgs, 0.200 mmol) in xylene
(5 ml) is heated at reflux (oil bath temp 150°C) for 24
25 h. The mixture is allowed to cool to room temperature
and the xylene removed under high vacuum overnight. The
solid residue is taken up in ethanol (10 ml) and
saturated potassium iodide solution (10 ml) followed by
water (10 ml) is added. The resulting solution is
30 extracted with methylene chloride and the extract dried
over magnesium sulphate, filtered and concentrated to
give a crude product. Flash column chromatography (10%
methanol in methylene chloride) of the crude material

gave the product as a red crystalline solid (45 mgs, 30%). V_{\max} ; 3000-2800; 1640; 1601; 1503; 1360; 1166 cm^{-1} . ^1H nmr δ , 8.71 (s, 1H); 7.96 (d, $J=9.3$ Hz, 2H); 7.14 (dd, $J=2.0$ Hz and 9.0 Hz, 2H); 6.695 (s, 2H); 4.84 (t, $J=7.9$ Hz, 2H); 3.36 (s, 12H); 0.884 (t, $J=7.0$ Hz, 3H).

While the various aspects of the present invention have been described and exemplified above in terms of certain preferred embodiments, various other embodiments may be apparent to those skilled in the art. For example, the present invention may be used to advantage in the study of viruses. Currently, it is extremely difficult to track viruses within model systems to determine the location in vivo where viral replication or pooling takes place. Using the compounds of this invention, it is possible to incorporate reporter molecules into the lipids of membrane viruses, using both the fluorescent and radio-imaging procedures outlined hereinbelow. As an example, it is not known where the virus HIV-I (AIDS) replicates or resides within the living animal. Such viruses could be labeled with the Indium or Iodine (gamma-emitting) forms of the compounds of this invention and washed free of unbound radio-active compounds. The labeled virus would then be injected and the animal imaged using a gamma camera. If the viruses were also labeled with a fluorescent form of the compounds of this invention, then the gamma imaging could be used to identify which organ is the reservoir for the virus and the organ could be removed, disaggregated into single cell suspension and the cells containing the viruses could be identified on the basis

- 76 -

of the fluorescence using flow cytometry or quantitative microscopy. This invention is, therefore, not limited to the embodiments specifically described and exemplified, but is capable of variation and
5 modification without department from the scope of the appended claims.

10

15

20

25


30

WHAT IS CLAIMED IS

1. A compound for binding in a compatible binding medium to the surface membrane of a viable bioparticle capable of physiological function, without appreciable detrimental effect on the viability or function of said bioparticle, said compound comprising a bio-affecting substance and at least one hydrocarbon substituent selected so that the compound is sufficiently non-polar as to have a surface membrane retention coefficient of at least about 90 during a 24 hour period in saline containing up to 10 percent serum and the percent change in said coefficient during said period being less than 10 percent, and further selected so that the compound solubility determination deviation for said compound is no more than 20 percent during 2 hours when dissolved in said binding medium, and provided that when said bio-affecting substance is a cyanine dye, the structure thereof is unsymmetrical.

2. A compound as claimed in claim 1, dissolved in a medium having an osmolarity between 260 mOs and 340 mOs, said medium being isotonic for the bioparticle to which the compound is to be bound.

3. A compound as claimed in claim 1, having the formula:



wherein B represents said bio-affecting substance and R and R_1 represent substituents independently selected from the group of hydrogen, alkyl, alkenyl, alkynyl, alkaryl or aralkyl, the hydrocarbon chains of which are linear or branched, said substituents being unsubstituted or substituted with one or more non-polar functional groups, one of R or R_1 having at least 12 linear carbon atoms and the sum of the linear carbon

atoms in R and R₁ totaling at least 23.


4. A compound as claimed in claim 1, wherein said bio-affecting substance comprises a diagnostic agent.

5. A compound as claimed in claim 4, wherein said diagnostic agent is a fluorescent substance.

6. A compound as claimed in claim 5, wherein said fluorescent substance is positively charged.

7. A compound as claimed in claim 5, wherein said fluorescent substance is selected from the group of cyanine, acridine, pyridine, anthraquinone, coumarin, quinoline, xanthene, phenoxazine, phenothiazine and hexatriene dyes and derivatives thereof.

8. A compound having the formula:



wherein R and R₁ are different and represent substituents independently selected from the group of hydrogen, alkyl, alkenyl, alkynyl, alkaryl or aralkyl, the hydrocarbon chains of which having from 1 to 30 carbon atoms, and being linear or branched, said substituents being unsubstituted or substituted with one or more non-polar functional groups, one of R or R₁ having at least 12 linear carbon atoms, and the sum of the linear carbon atoms in R and R₁ being at least 23;


X and X₁ may be the same or different and represent O, S, C(CH₃)₂ or Se;

Y represents a linking group selected from -CH=, -CH=CH-CH=, -CH=CH-CH=CH-CH=, or -CH=CH-CH=CH-CH=CH-CH=;

Z represents a substituent selected from the group H, alkyl, OH, NH₂, COOH, CONH₂, SO₃H, SO₂NH₂, CONH-alkyl, CON-(alkyl)₂, NH-acyl, -O-alkyl, NH-alkyl, or N(alkyl)₂, SH, S-alkyl, NO₂ or halogen, the alkyl groups comprising said Z substituents having from 1 to 3 carbon atoms;

and A represents a biologically compatible anion.

9. A compound having the formula:



wherein R and R₁ are different and represent alkyl substituents, having from 1 to 30 carbon atoms, and being linear or branched, unsubstituted or substituted with halogen, one of R or R₁ having at least 12 linear carbon atoms and the sum of the linear atoms in R and R₁ being at least 23;

Z represents a substituent selected from the group H, or lower alkyl having from 1 to 3 carbon atoms; and

A represents a biologically compatible anion.


10. A compound as claimed in claim 9, which is 3-n-Pentyl-3'-n-octadecyloxacarbocyanine Iodide.

11. A compound as claimed in claim 9, which is 3-n-Octyl-3'-n-octadecyloxacarbocyanine Iodide.

12. A compound as claimed in claim 9, which is 3-n-Propyl-3'-n-eicosanyloxacarbocyanine Iodide.

13. A compound as claimed in claim 9, which is 3-n-Propyl-3'-n-docosanyloxacarbocyanine Iodide.

14. A compound having the formula:



wherein R represents a substituent selected from the group of alkyl, alkenyl, alkynyl, alkaryl or aralkyl, the hydrocarbon chain of which is linear or branched, said substituent being unsubstituted or substituted with one or more non-polar functional groups, and having at least 23 linear carbon atoms;

Z represents a substituent selected from the group H, alkyl, OH, NH₂, COOH, CONH₂, SO₃H, SO₂NH₂, CONH-alkyl, CON-(alkyl)₂, NH-acyl, -O-alkyl, NH-alkyl, or N(alkyl)₂, SH, S-alkyl, NO₂, halogen, the alkyl groups comprising said Z substituents having from 1 to 3 carbon atoms; and

A represents a biologically compatible anion.

15. A compound, as claimed in claim 14, which is 3,6-bis (dimethylamino)-10-n-hexacosanyl acridinium iodide.

16. A compound, as claimed in claim 4, wherein said diagnostic agent comprises a chelate-metal complex.

17. A compound as claimed in claim 16, wherein said chelate-metal complex comprises a metal ion selected from the transition metal series whose atomic number is from 21-29, the lanthanide series whose atomic number is 59-66 and the actinide series whose atomic number is 91, said ion influencing the relaxation times of nearby nuclei so as to be detectable by magnetic resonance imaging.


18. A compound as claimed in claim 16, wherein said chelate-metal complex comprises a paramagnetic metal ion selected from the group of Gd, Cr, Dy, Ni, Cu, Fe and Co.

19. A compound as claimed in claim 16, wherein said chelate-metal complex comprises a metal isotope selected from the transition metal series whose atomic number

is from 21-49, or selected from the group of $^{43}_{19}\text{K}$, $^{199}_{81}\text{Tl}$, $^{131}_{55}\text{Cs}$ or $^{203}_{80}\text{Hg}$ said isotope being detectable by gamma imaging.

20. A compound as claimed in claim 15, wherein said chelate-metal complex comprises a metal isotope exhibiting the Mossbauer effect.

21. A chelating agent having the formula:



, n being a number from 0 to 2; m being a number from 0 to 2; and p being either 0 or 1,

wherein R_1 , R_2 , R_3 and R_4 independently represent substituents selected from the group of:

H, CH_2COOH

$\begin{array}{c} \text{R}_6 \\ | \\ \text{COCH-SH} \end{array}$; $\begin{array}{c} \text{R}_6 \quad \text{R}_7 \\ | \quad | \\ \text{CH-CH-SH} \end{array}$; $\begin{array}{c} \text{R}_6 \quad \text{R}_7 \\ | \quad | \\ \text{CH-C=NOH} \end{array}$; $\begin{array}{c} \text{R}_6 \\ | \\ \text{CH-COOR}_9 \end{array}$;

$\begin{array}{c} \text{R}_6 \quad \text{R}_7 \\ | \quad | \\ \text{CH-CHNHCOCH}_3 \end{array}$; $\begin{array}{c} \text{R}_7 \quad \text{R}_6 \\ | \quad | \\ \text{COCHNHCOCH}_3 \end{array}$; $\begin{array}{c} \text{R}_6 \\ | \\ \text{CHCONHCH}_3 \end{array}$;

$\text{C}_1\text{-C}_{30}$ alkyl, $\text{C}_1\text{-C}_{30}$ alkenyl, $\text{C}_1\text{-C}_{30}$ alkynyl, and unsubstituted or substituted aryl or aralkyl, said last-mentioned substituents being selected from hydroxyl, halogen, thiol, $\text{C}_1\text{-C}_{30}$ alkyl, $\text{C}_1\text{-C}_{30}$ alkenyl, $\text{C}_1\text{-C}_{30}$ alkynyl or aryl or aralkyl; O-($\text{C}_1\text{-C}_{30}$ alkyl, alkenyl or alkynyl); S-($\text{C}_1\text{-C}_{30}$ alkyl, alkenyl or alkynyl); NH($\text{C}_1\text{-C}_{30}$ alkyl, alkenyl or alkynyl); N^+R_{11} ($\text{C}_1\text{-C}_{30}$ alkyl, alkenyl or alkynyl)₂; N($\text{C}_1\text{-C}_{30}$ alkyl, alkenyl or alkynyl)₂

W represents CH_2 or $\text{C}=\text{O}$;


X represents CH or N ;

R_5 and R_5' independently represent H , $\text{CH}_2\text{CO}_2\text{H}$, or $\text{Y}-\text{R}_8$;

Y represents the linking group O , $\text{C}=\text{O}$, S , $(\text{CH}_2)_x$ or Se , x being a number from 0 to 5;

R_6 and R_7 independently represent H or C_1 to C_2 alkyl;

R_8 represents a substituent selected from the group of $-\text{NH}(\text{C}_1\text{-C}_{30}$ alkyl, alkenyl, or alkynyl), $\text{N}(\text{C}_1\text{-C}_{30}$ alkyl, alkenyl or alkynyl) $_2$, $\text{N}^+\text{R}_{11}(\text{C}_1\text{-C}_{30}$ alkyl, alkenyl or alkynyl) $_2$, $\text{C}_1\text{-C}_{30}$ alkyl, $\text{C}_1\text{-C}_{30}$ alkenyl, $\text{C}_1\text{-C}_{30}$ alkynyl, unsubstituted or substituted aryl or aralkyl, said last-mentioned substituents being selected from the group of H , alkyl to C_{30} , alkenyl to C_{30} , alkynyl to C_{30} , alkaryl, aralkyl, $-\text{O}$ -alkyl to C_{30} , $-\text{O}$ -alkenyl to C_{30} , O -alkynyl to C_{30} , $-\text{O}$ -aralkyl, $-\text{NR}_9$ -alkyl to C_{30} , $-\text{NR}_9$ -alkynyl to C_{30} , $-\text{NR}_9$ -alkenyl to C_{30} , $-\text{NR}_9$ -aralkyl, S -alkyl to C_{30} , $-\text{S}$ -alkenyl to C_{30} , S -alkynyl to C_{30} , $-\text{S}$ -aralkyl, $\text{N}^+\text{R}_9\text{R}_{11}$ -alkyl to C_{30} , $\text{N}^+\text{R}_9\text{R}_{11}$ -alkenyl to C_{30} , $\text{N}^+\text{R}_9\text{R}_{11}$ -alkynyl to C_{30} , $-\text{NHCOR}_9$,



y being a number from 0 to 5;

R_9 represents a substituent selected from the group of

H , $\text{C}_1\text{-C}_{30}$ alkyl, $\text{C}_1\text{-C}_{30}$ alkenyl, $\text{C}_1\text{-C}_{30}$ alkynyl or aralkyl;


R_{10} represents a substituent selected from the

group of C_1 - C_{30} alkyl, C_1 - C_{30} alkenyl, C_1 - C_{30} alkynyl, alkaryl or aralkyl;

R_{11} represents a substituent selected from the group of H or C_1 to C_3 alkyl; and

wherein at least one of the substituents R_1 , R_2 , R_3 , R_4 , R_8 , R_9 or R_{10} has a minimum of 23 carbon atoms, or the sum of the linear carbon atoms in any two of said substituents totals at least 23 carbon atoms.

22. A chelating agent having the formula:



wherein R_1 represents $COCH_2SH$, $CH(CH_3)C(CH_3)=NOH$ or $CH_2C(Me)_2SH$;

X represents a carbonyl or methylene; and


R_2 represents a substituent selected from the group of NHR_3 , NR_3R_4 or $^+NR_3R_4R_5$;

R_3 and R_4 represent substituents independently selected from the group of C_1 - C_{30} alkyl, C_1 - C_{30} alkenyl, C_1 - C_{30} alkynyl, aralkyl or alkaryl;

R_5 represents H or C_1 to C_2 alkyl; and at least one of the substituents R_3 or R_4 has a minimum of 23 linear carbons, or the sum of linear carbon atoms in R_3 and R_4 totals at least 23 carbon atoms.

23. A compound as claimed in claim 22 complexed with Technetium.

24. A chelating substance of the formula:



wherein n is 0 or 2; m is 1 or 2; X represents CH or N; one of R_1 or R_2 is $\text{CH}_2\text{CO}_2\text{H}$ and the other of R_1 or R_2 represents a substituent selected from the group of alkyl, alkenyl, alkynyl, aralkyl or alkaryl, or $\text{CH}_2\text{-C}_6\text{H}_4\text{-NHCO-}$ (alkyl, alkenyl, alkynyl, aralkyl, alkaryl), the hydrocarbon chain of which is linear or branched and contains at least 23 linear carbon atoms.

25. A compound as claimed in claim (24) complexed with Indium.

26. A compound as claimed in claim 4, wherein said diagnostic agent comprises a radioisotope.

27. A compound as claimed in claim 26, wherein the radioisotope constituent of said diagnostic agent is selected from the group of radioactive hydrogen, carbon, nitrogen, phosphorus, fluorine, chlorine, iodine, sulphur and selenium.

28. A compound as claimed in claim (1), wherein said bio-affecting substance is a therapeutic agent.

29. A compound as claimed in claim (28), wherein said therapeutic agent comprises a proteinaceous substance.

30. A compound as claimed in claim 29, wherein said proteinaceous substance is selected from the group of toxins, hormones, enzymes, antigens, antibodies, and antibody fragments.

31. A compound as claimed in claim (28), wherein said therapeutic agent is selected from the group of chemotherapeutic or radiotherapeutic drugs or photoactivatable compounds.

32. A compound as claimed in claim 28, wherein said

therapeutic agent comprises a carbohydrate.

33. A compound as claimed in claim 32, wherein said carbohydrate is selected from the group of glycosaminoglycans or sialic acids.

34. A composition for binding to the surface membrane of a viable bioparticle capable of physiological function, a bio-affecting substance in a compatible binding medium, said composition comprising a compound in the form of a bio-affecting substance bearing at least one hydrocarbon substituent selected so that the compound is sufficiently non-polar as to have a surface membrane retention coefficient of at least about 90 during a 24 hour period in saline containing up to 10 percent serum and the percent change in said coefficient during said period being less than 10 percent, and further selected so that the compound solubility determination deviation of the compound is no more than 20 percent during two hours when dissolved in said binding medium, and a compatible binding medium in which said compound is dissolved, said medium being iso-osmotic for the bioparticle to which the compound is to be bound.

35. A composition as claimed in claim 34, wherein said medium has iso-osmotic properties at between 260 mOs and 340 mOs and is isotonic for the bioparticle to which the compound is to be bound.

36. A composition as claimed in claim 34, wherein said compound is of the formula, $R-B-R_1$ wherein B represents said bio-affecting substance and R and R_1 represent substituents independently selected from the group of hydrogen, alkyl, alkenyl, alkynyl, alkaryl or aralkyl, the hydrogen chains of which are linear or branched, said substituents being unsubstituted or

substituted with one or more non-polar functional groups, one of R or R₁ having at least 12 linear carbon atoms and the sum of the linear carbon atoms in R and R₁ totaling at least 23, and said medium is selected from the group of a sugar, a sugar-alcohol, an amino acid, a Good's buffer or a combination thereof.

37. A method for preparing a viable bioparticle capable of physiological function bearing a bio-affecting substance, for exerting a site-specific predetermined effect in vivo, said method comprising;

providing in a compatible binding medium a compound comprising a bio-affecting substance and at least one hydrocarbon substituent selected so that the compound is sufficiently non-polar as to have a surface membrane retention coefficient of at least about 90 during a 24 hour period in saline containing up to 10 percent serum and the percent change in said coefficient during said period being less than 10 percent, and further selected so that the solubility determination deviation for the compound is no more than 20 percent during 2 hours when dissolved in said binding medium, and

contacting said compound with said bioparticle in said binding medium under conditions causing binding of said compound to said bioparticle, said binding occurring without appreciably diminishing viability or function of said bioparticle, whereby said predetermined effect may be exerted at said in vivo site.

38. A method as claimed in claim 37, wherein said bioparticle is a eukaryotic cell.

39. A method for exerting a site-specific predetermined effect in vivo by exposing said site to a bio-affecting substance capable of producing said predetermined effect, said method comprising;

providing a viable bioparticle capable of physiologic function bearing said bio-affecting substance, prepared as in claim 37; and

introducing said bioparticle in vivo, whereby said bio-affecting substance exerts said effect at said site.

40. A method as claimed in claim 39, wherein said bioparticle is a eukaryotic carrier cell.

41. A method as claimed in claim 40, wherein said carrier cell is provided with a diagnostic agent as the bio-affecting substance bound thereto, for determining the physiological condition of said in vivo site.

42. A method as claimed in claim 40, wherein said carrier cell is provided with a therapeutic agent as the bio-affecting substance bound thereto, for altering the physiological condition of said carrier cell, a cell group in vivo, or site in vivo.

43. A compound as claimed in claim 1, wherein said hydrocarbon substituent comprises a diagnostic agent.

44. A compound as claimed in claim 43, wherein said diagnostic agent is a radioisotope.

45. A compound as claimed in claim 44, wherein said radioisotope is selected from the group of radioactive hydrogen, carbon, nitrogen, phosphorus, fluorine, chlorine, iodine, sulphur and selenium.


AMENDED CLAIMS

[received by the International Bureau on 27 October 1989 (27.10.89)
original claim 20 amended; other claims unchanged (1 page)]

is from 21-49, or selected from the group of $^{43}_{19}\text{K}$, $^{199}_{81}\text{Tl}$, $^{131}_{55}\text{Cs}$ or $^{203}_{80}\text{Hg}$ said isotope being detectable by gamma imaging.

20. A compound as claimed in claim 16, wherein said chelate-metal complex comprises a metal isotope exhibiting the Mossbauer effect.

21. A chelating agent having the formula:



, n being a number from 0 to 2; m being a number from 0 to 2; and p being either 0 or 1,

wherein R₁, R₂, R₃ and R₄ independently represent substituents selected from the group of:

H, CH₂COOH

$\begin{array}{c} \text{R}_6 \\ | \\ \text{COCH-SH} \end{array}$; $\begin{array}{c} \text{R}_6 \quad \text{R}_7 \\ | \quad | \\ \text{CH-CH-SH} \end{array}$; $\begin{array}{c} \text{R}_6 \quad \text{R}_7 \\ | \quad | \\ \text{CH-C=NOH} \end{array}$; $\begin{array}{c} \text{R}_6 \\ | \\ \text{CH-COOR}_9 \end{array}$;

$\begin{array}{c} \text{R}_6 \quad \text{R}_7 \\ | \quad | \\ \text{CH-CHNHCOCH}_3 \end{array}$; $\begin{array}{c} \text{R}_7 \quad \text{R}_6 \\ | \quad | \\ \text{COCHNHCOCH}_3 \end{array}$; $\begin{array}{c} \text{R}_6 \\ | \\ \text{CHCONHCH}_3 \end{array}$;

C₁-C₃₀ alkyl, C₁-C₃₀ alkenyl, C₁-C₃₀

alkynyl, and unsubstituted or substituted aryl or aralkyl, said last-mentioned substituents being

selected from hydroxyl, halogen, thiol, C₁-C₃₀

alkyl, C₁-C₃₀ alkenyl, C₁-C₃₀ alkynyl or

aryl or aralkyl; O-(C₁-C₃₀ alkyl, alkenyl or

alkynyl); S-(C₁-C₃₀ alkyl, alkenyl or alkynyl);


NH(C₁-C₃₀ alkyl, alkenyl or alkynyl);

N⁺R₁₁ (C₁-C₃₀ alkyl, alkenyl or alkynyl)₂;


N(C₁-C₃₀ alkyl, alkenyl or alkynyl)₂


FIGURE 1

A.




B.






3/7

FIGURE 3




4/7

FIGURE 4




PKH-3


CELL NUMBER




DAY 0




DAY 1



DAY 2



DAY 3




DAY 4


LOG FLUORESCENCE

FIGURE 5A


PKH/CMPD-1




DAY 0




DAY 1



DAY 2



DAY 3




DAY 4


FIGURE 5B

LOG FLUORESCENCE

PKH-4




DAY 0




DAY 1


FIGURE 5C



DAY 2



DAY 3



DAY 4

LOG FLUORESCENCE

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US89/00087

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC INT. CL. ⁴ A61K 49/00 C07D 219/04 C07D 263/62 C07C 87/14 U.S. CL. 424/9 546/103 548/219 564/511		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
U.S.	424/1.1,9; 534/10,14,15; 548/100,219,455; 556/1; 546/102,103,104,105,107; 564/153,154,291,511,512; 562/426,442,443,450,556,565	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ⁹	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	US, A, 4,110,116 BERETTA ET AL. 29 AUGUST 1978, see column 2, lines 5-68 and column 5, lines 40-45.	8-13
Y	US, A, 4,652,519 WARSHAWSKY ET AL. 24 MARCH 1987, see column 2, lines 25-38	21
A	GB, A, 723,316 BERSWORTH 9 FEBRUARY 1955.	
A	US, A, 3,228,904 MORRIS ET AL. 11 JANUARY 1966.	
A	FR, A, 1,477,402 COMMERCIAL SOLVENTS CORPORATION 21 APRIL 1967.	
A	DE, B, 1,251,764 BOEHRINGER SOHN 12 OCTOBER 1967.	
A	US, A, 3,352,791 SHEEHAN ET AL. 14 NOVEMBER 1967.	
A	US, A, 4,352,751 WIEDER ET AL. 05 OCTOBER 1982.	
<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p>* Special categories of cited documents:¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 48%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
30 AUGUST 1989		11 SEP 1989
International Searching Authority		Signature of Authorized Officer
ISA/US		 John S. Maples

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	US, A, 4,419,511 RAUE 06 DECEMBER 1983.	
A	US, A, 4,460,790 REINEHR ET AL. 17 JULY 1984.	
A	US, A, 4,670,545 FRITZBERG ET AL. 02 JUNE 1987.	
A	US, A, 4,705,889 HENDRICKS ET AL. 10 NOVEMBER 1987.	

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers _____, because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim numbers _____, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claim numbers _____, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☒ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This International Searching Authority found multiple inventions in this international application as follows:

I. Claims 1-7, 16-18, 28-43 drawn to a compound/composition/method of use classified in class 424 subclass 9.

II. Claims 8-13 drawn to a bicyclo compound classified in class 548 subclass 100. (CONTINUED)

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

☐ The additional search fees were accompanied by applicant's protest.

☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM THE LACK OF UNITY OF
INVENTION-DETAILED REASONS FOR HOLDING LACK OF UNITY OF
INVENTION

- I. Claims 1-7, 16-18, 28-43 drawn to a compound/composition/method of use classified in class 424 subclass 9.
- II. Claims 8-13 drawn to a bicyclo compound classified in class 548 subclass 100.
- III. Claims 14-15 and 20 drawn to a tricyclo compound classified in class 546 subclass 103.
- IV. Claims 19, 26, 27, 44 and 45 drawn to a radioactive compound classified in class 424 subclass 1.1.
- V. Claims 21 and 22 drawn to a polyamine compound classified in class 564 subclass 153.
- VI. Claim 23 drawn to a radioactive triamine compound classified in class 534 subclass 14.
- VII. Claim 24 drawn to a polycarboxylic acid compound classified in class 562 subclass 443.
- VIII. Claim 25 drawn to a metal complex compound classified in class 556 subclass 1.

The above inventions lack unity under PCT Rule 13 since, for example, the Group II compound is materially different than the Group III compound since the Group II compound contains two bicyclo rings while the Group III compound contains a tricyclo ring system. Groups V, VII and VIII likewise lack unity since they are directed to materially different compounds than either the Group II or Group III compounds. Groups IV and VI comprise radioactive moieties however, they likewise are directed to two different basic compound structures. Finally, Group I is drawn to a compound/composition/method of use and the compounds in each of the other Groups could be used in a substantially different composition and for a different use such as an in vitro assay.

FURTHER INFORMATION CONTINUED FROM VI. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

III. Claims 14-15 and 20 drawn to a tricyclo compound classified in class 546 subclass 103.

IV. Claims 19, 26, 27, 44 and 45 drawn to a radioactive compound classified in class 424 subclass 1.1.

V. Claims 21 and 22 drawn to a polyamine compound classified in class 564 subclass 153.

VI. Claim 23 drawn to a radioactive triamine compound classified in class 534 subclass 14.

VII. Claim 24 drawn to a polycarboxylic acid compound classified in class 562 subclass 443.

VIII. Claim 25 drawn to a metal complex compound classified in class 556 subclass 1.